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ABSTRACT 
Muscle injury therapy employs human primary satellite skeletal muscle cells seeded onto 
microthreads. However, the cell culture process prior to seeding that would assure maintenance 
of the myogenic potential has not been optimized. This cell line has both adherent and non-
adherent cell populations; non-adherent population displaying a higher myogenic potential. The 
team was challenged with the optimization of growth and myogenic potential, either through the 
use of device or the optimization of the cell culture process.  
The team focused on creating a design that was commercializable, user friendly, and 
optimized the production of non-adherent cells. In addition the team determined that this design 
must be safe for the user and for the cells, and must yield a myogenic potential of at least 30%. 
By using these objectives and constraints, the team developed a series of alternative designs, 
and determined that a process engineering approach of optimizing the medium was best suited 
to meet the client needs. For this project, the modified the concentration of growth factors in the 
current proliferation medium recipe to observe the effect of cell proliferation, myotube formation, 
and myogenic potential.  
Initially, the team started with 23 treatments for preliminary testing of a cell count, 
proliferation, and differentiation percentages. The top ten treatments that produced the greatest 
results were verified using the same tests. From here, the top six treatments were chosen to 
conduct MyoD expression and myogenic potential assays. Based on these results the top two 
treatment mediums were determined and a cost-benefit analysis was conducted.  
After conducting these assays, it was found that culturing the cells without EGF 
produced a less expensive and more beneficial process than that of the current medium. 
Compared to the control, the No EGF had a similar proliferation percent (31.8% ± 14.4 vs 34.4% 
± 13.4). In addition, it had a greater population percentage of non-adherent cells (32.7% ± 9.6 
vs. 23.3% ± 7.7) and almost doubled the myogenic potential (47.3% ± 6.5 vs. 27.1% ± 2.2). In 
addition, the cost-benefit analysis confirmed that this medium was nearly $1,000 less costly 
than the control to move forward with in a clinical setting of treating a wound defect of 15 cubic 
cm.    
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EXECUTIVE SUMMARY 
I. INTRODUCTION 
Human skeletal muscle is responsible for voluntary movement to complete basic daily 
functions [1]. However, injuries can often arise to the muscle. After these injuries, skeletal 
muscle has the unique ability to regain function, provided the muscle loss is not too high [2]. 
When injury occurs, the muscle first experiences inflammation and the fibers rapidly degrade. 
Following this, new tissue is formed from satellite cell proliferation and differentiation [2][3]. 
Finally, tissue remodeling occurs, which results in the alignment of myofibers and integration 
into the muscle [3]. However, in large-scale muscle injuries, the wound site is not able to 
regenerate muscle. As a result, a fibrin matrix is created, resulting in non-functional, collagen 
scar tissue [4]. 
Research is being conducted on human skeletal muscle derived cell-loaded fibrin 
microthread bundles to aid in functional tissue regeneration [4]. However, as the primary human 
skeletal satellite cells are cultured, the myogenic potential of these cells are lost. From previous 
research, culture of the satellite cells using a combination of growth factors leads to replication 
of cells in the non-adherent state.  Further, it has been found that the myogenic potential of cells 
can be preserved over time by selectively subculturing the non-adherent cell population. 
Therefore, the goal of this project was to engineer a cell culture process to optimize the growth 
kinetics of satellite cells according to the proportion of cells in the non-adherent state. 
To accomplish this, the concentrations of selected components of the cell culture 
medium were varied to determine their effect on the proportion of non-adherent satellite cells. 
The subsequent effect on myogenic potential was determined by inducing the cells to 
differentiate by culture in differentiation medium and calculating the myogenic index.  An 
economic analysis was also performed to determine the cost-benefit of implementing the 
optimized process.   
II. PROCEDURE 
A. CELL CULTURE 
1) Media Composition: Proliferation media is comprised of 54% Dulbecco’s Modified 
Eagles Medium (DMEM) (Corning), 36% F12 Medium (Corning), 10% FCIII (Hyclone), 
4mM glutamine (Cellgro), 1X penicillin/streptomycin (EMD), and various amounts of four 
growth factors (FGF2, EGF, HGF, and IGF). Different concentrations and combinations 
of these growth factors were used in each media condition to assess the effects on 
cellular growth. The differentiation media was made up of 58.2% DMEM, 38.8% F12, 2% 
Horse serum (Hyclone), 1% ITS, 4mM glutamine, and 1X penicillin/streptomycin (EMD). 
2) Subculturing Adherent and Non-adherent Cells: Human primary satellite cells were 
obtained from a Worcester Polytechnic Institute frozen stock, and were grown at 37oC 
with 5% CO2 in proliferation media. Cells were seeded at 10,000 cells per well on Nunc 
24-well plates and cultured. 
B. CELL COUNTS 
Through imaging and microscopy the percent of adherent to non-adherent cells were 
determined. Using a Zeiss inverted microscope, five images were taken after cells were cultured 
for three days. Images were taken at five identical spots in each well to standardize the process. 
The team gathered a total cell count for each condition using a hemocytometer. 
  iv 
C. BROMODEOXYURIDINE (BRDU) CELL PROLIFERATION ASSAY 
BrdU incorporation assays were completed to determine the effect of each culture 
condition on cell proliferation rate. Cells were plated at 10,000 cells/well in a 24- well plate for 
each of the media conditions. After 48 hours 1μL of BrdU labeling reagent (Invitrogen) was 
added to each well. After an additional 24 hours, cells were fixed with 500 μL of formaldehyde 
(Sigma), permeabilized with 0.02% Triton X-100 (Fischer) and 1.5N HCl, and treated with -20oC 
methanol. Primary antibodies, secondary antibodies and their concentrations were anti-BrdU 
1:100 and Alexafluor-488 1:500, respectively (DSHB, Invitrogen). Nuclei were counterstained 
with 0.5 mg/ml Hoechst 33342 (CalBioChem). Images were taken using the same locations as 
previously described with a Zeiss inverted epi-fluor microscope and AxioVision Software. 
D. IMMUNOCYTOCHEMISTRY FOR MYOSIN HEAVY CHAIN 
Immunocytochemistry (ICC) for myosin heavy chain allows for identification of 
differentiated muscle cells. Cells were grown for 24 hours in each treatment media and then 
cultured in differentiation medium for 10 days. Cells were fixed using the same procedure as for 
the BrdU above, except the HCl treatment was eliminated. Myosin heavy chain was detected 
using the primary antibody MF20 at 1:500 dilution (DSHB) followed by secondary antibody 
Alexaflour-488 1:500 dilution (Invitrogen). Nuclei were counterstained with 0.5 mg/ml Hoechst 
33342 (CalBioChem). Fluorescence was observed using a Zeiss inverted epi-fluor microscope 
and AxioVision Software. 
E. IMMUNOCYTOCHEMISTRY FOR MYOGENIC POTENTIAL 
To test for myogenic potential and visual recognition of myotubes, two primary and two 
secondary antibodies were used to target MyoD and myosin heavy chain in mirror wells. The 
primary and secondary antibodies and their concentrations were anti-MyoD1 antibody [5.2F] 
1:1000 (Abcam) and MF20 1:500 (DSHB). Isotype-appropriate secondary antibodies labeled 
with Alexafluor-488 and Alexafluor-568 at a concentration of 1:1000 were also used. This assay 
was conducted at four time points: 0, 3, 5, and 10 days, to compare the percentage of cells 
expressing MyoD to the same percentage of late expressing myosin heavy chain. In addition, 
multinucleated myotubes were observed to measure myotube formation and fusion index. 
III. RESULTS 
A. CELL COUNTS 
After the cells were cultured for three days in their respective media compositions the 
adherent and non-adherent cell populations were counted. As seen in Table 1 below, it was 
found that the +50% FGF2 and No EGF conditions showed to have a larger cell population. In 
addition, it was found that +50% FGF2, No EGF, -50% EGF, +50% EGF, and -50% HGF had a 
sizeable population of non-adherent cells which were all above that for control medium.  
Table 1: Cell Count Data for Top 10 Treatments 
 All GFs (Control) 
Just 
FGF2 
No 
FGF2 
-50% 
FGF2 
+50% 
FGF2 No EGF 
-50% 
EGF 
+50% 
EGF 
-50% 
HGF No IGF 
Total 
Cell 
Count 
78333 
± 2887 
48333 
± 10408 
53333 
± 11547 
68333 
± 2887 
71667 
± 20207 
73333 
± 2887 
65000 
± 5000 
53333 
± 7638 
36667 
± 2887 
43333 
± 14434 
Percent 
Non-
Adherent 
23.4% 
± 7.7 
21.7% 
± 8.1 
17.5% 
± 8.8 
24.6% 
± 18.0 
35.5% 
± 7.8 
32.7% 
± 9.6 
28.8% 
± 9.6 
36.2% 
± 9.8 
29.8% 
± 13.1 
26.8% 
± 13.8 
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B. BRDU PROLIFERATION ASSAY 
Cells were seeded at 10,000 cells per well and cultured for two days. BrdU labeling 
reagent was added at this time, and then cells were allowed to differentiate for 24 additional 
hours before the assay was completed. After completing the BrdU assay, it was observed that 
four treatment mediums displayed a BrdU positive cell percentage of greater than 30%. These 
treatments include the control of All GFs, +50% FGF2, No EGF and No IGF.  
C. IMMUNOCYTOCHEMISTRY FOR MYOSIN HEAVY CHAIN 
Cells were seeded at 10,000 cells per well, and cultured for three days in treatment 
medium. Cells were then placed into differentiation medium where they were allowed to 
differentiate for 10 days. After completing the assay, it was observed that three treatment media 
produced a percent differentiation of greater than 30%. These treatments include the control of 
All GFs, Just FGF2, and +50% FGF2. However, while these cells were highly differentiated, 
most of the cells produced only mononucleated myosin positive cells.  
D. IMMUNOCYTOCHEMISTRY FOR MYOGENIC POTENTIAL 
Using data from the cell count, BrdU, and ICC for myosin heavy chain, the team selected 
the top six treatments that yielded the best results. Cells were seeded at 10,000 cells per well 
for three days in treatment medium. Cells were then placed into differentiation medium and 
differentiated for 0, 3, 5, and 10 days and stained for either MyoD or myosin heavy chain. Cells 
that were stained for MyoD showed an increase in expression through Day 5. After Day 5, 
however, there was a drastic decline in MyoD expression in all treatments.  
Figure 1 below displays the data obtained for cells stained to identify myosin heavy 
chain over a 10-day period. This data was used to calculate the myogenic potential through the 
use of a fusion index. As shown in the Figure, all treatments show a similar trend in 
differentiation, however two treatments, No EGF and +50% FGF2, maintained a high myogenic 
potential throughout the differentiation process. In addition, these treatments produced the 
greatest myogenic potential and were greater than the control.  
 
Figure 1: Myogenic Potential for Top Six Treatments.  
IV. DISCUSSION 
By analyzing the cell proliferation rate by cell count and BrdU incorporation, and 
differentiation of the cells, the team determined the top six treatments to test for myogenic 
potential. As previously mentioned, the non-adherent population is believed to be a leading 
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factor in preserving myogenic potential for satellite cell amplification in vitro. It was found that all 
of the treatments, with the exception of the No FGF2 treatment, yielded a higher percent non-
adherent population than the currently used medium. Further, +50% FGF2 and No EGF also 
demonstrated a high cell count as well as a high percent non-adherent population.  
In order to scale up this process for clinical use, cells need to demonstrate a high 
proliferation rate, and therefore treatments that produced a higher amount of BrdU positive cells 
were identified. Based on the BrdU results, only two conditions (+50% FGF2 and No IGF) 
showed greater proliferation than the medium used currently. In addition, the differentiation 
capability of the cells was determined through the ICC assay for myosin heavy chain. By 
analyzing this data, the top six treatments that provided a total cell count, non-adherent cell 
count, BrdU positive cell count, and differentiation percent were selected for further 
investigation. These treatments were the control of All GFs, Just FGF2, +50% FGF2, No EGF, -
50% HGF and No IGF.  
These treatments were then tested for the expression of MyoD and for their myogenic 
potential. MyoD is a transcription factor that is up-regulated during the early phases of 
differentiation. In analyzing this in conjunction with the expression of myosin, the myogenic 
potential was determined. Upon reviewing Table 1 and Figure 1, it can be observed that the two 
treatments that produced the greatest non-adherent population also produced the greatest and 
most consistent myogenic potential. This supports the previous hypothesis that the non-
adherent population plays a key role in preserving the satellite cell myogenic potential.  
A cost-benefit analysis was conducted on the two treatments that yielded the highest 
myogenic potential (+50% FGF2 and No EGF). This cost analysis was based on the amount of 
media needed to scale up from 500,000 cells to 30 billion cells (the amount needed to treat a 15 
cubic cm wound). The media currently being used would cost roughly $118,500; the +50% 
FGF2 medium would cost roughly $132,500; and the No EGF medium would cost roughly 
$117,600. Not only was the No EGF treatment medium the least expensive, but it was also 
produced the greatest myogenic potential. In addition, further statistical analysis showed that 
this medium produced the most reproducible and reliable process, as indicated by the low 
standard deviations.   
V. FUTURE RECOMMENDATIONS 
With the No EGF treatment selected, there is further research that should be conducted 
to verify and further optimize this process. These include: 
• Verifying the long term effects of the treatment medium on the cells 
• Altering ambient oxygen levels and substrate surfaces 
• Conducting a single cell contraction assay to verify the functionality of the cells 
• Exploring the possibility of using a device to further optimize the process 
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1. INTRODUCTION 
Skeletal muscle is a large component of the human body and constitutes 40-45% of the 
human body mass. Unfortunately, injuries often arise to this tissue, primarily due to sports 
injuries, combat trauma, or motor vehicle accidents. However, skeletal muscle has a large 
capability to regenerate, largely in part due to progenitor satellite cells found in the muscle 
tissue. While these cells aid in muscle regeneration, they are unable to fully heal a large-scale 
injury wound due to scar tissue formation, leading to volumetric muscle loss (Turner and 
Badylak, 2012). 
Currently, in the Page Lab is researching methods to reduce the volumetric loss of 
muscle. One method includes implanting cell-loaded microthreads into wound site. Through this 
process, some degree of skeletal muscle tissue and functionality can be regenerated with 
minimal scar tissue formation (Page et al., 2011). Unfortunately, the myogenic potential of 
satellite cells is lost with each successive passage, and in order to be used in a clinical setting, 
their needs to be a process to scale up the production of these cells. In addition, it has been 
found that both adherent and non-adherent populations exist in this cell culture, and it is 
believed that the non-adherent population is correlated to myogenic potential.  
The goal of this project was to improve the myogenic potential and growth of human 
primary satellite cells. This was achieved by developing and optimizing a cell culture process, 
which improved the percent non-adherent cells and the myogenic potential. The cell culture 
medium was identified as an area for improvement. In order to meet the goal, a series of 
immunocytochemistry and cell counting assays were completed on various treatment mediums. 
These assays highlighted the cell proliferation, differentiation, total population, and the cellular 
potential to form functioning muscle tissue.  By process engineering, the team was able to 
determine a final optimized medium and conduct a cost-benefit analysis.  
 The following chapters of the report contain a literature review outlining relevant 
information and literature pertaining to skeletal muscle and satellite cells; a project strategy 
outlining the objectives and constraints used to revise the client statement; alternative designs 
and methods used to determine the process engineering approach; preliminary testing and 
results; preliminary data verification; final design results and selection of a optimized medium; 
and finally the team’s conclusions and further recommendations.  
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2. LITERATURE REVIEW 
This project explored strategies to enhance the propagation and myogenic potential of 
human primary satellite cells in vitro. This chapter assesses the relevant background and 
literature on skeletal muscle tissue, skeletal muscle regeneration, engineering skeletal muscle, 
in vitro cell culture environments and medium components, non-adherent cells as well as 
different tests to monitor the growth of cells.  
2.1 SKELETAL MUSCLE  
There are three types of muscle found within the body: cardiac, skeletal, and smooth. The 
skeletal muscle is responsible for voluntary movement within the body. Without skeletal muscle, 
the human body would not be able to complete the most basic daily functions. Cardiac and 
smooth muscle are responsible for involuntary muscle contractions within the body (Shier, 
2009). The following section discusses the skeletal muscle structure and describes the 
mechanism of how it functions.  
2.1.1 SKELETAL MUSCLE HIERARCHY 
The structure of skeletal muscles can be described as a decreasing hierarchal structure. 
The top-most layer, the fascia, is connective tissue that is composed of collagen. This 
connective tissue anchors the muscle to the bone. The next level in the muscle hierarchy is 
bundles of fascicles. Each fascicle contains bundles of muscle fibers, which are composed of 
myofibrils. Myofibrils contract when stimulated. Figure 1 below shows the structure of a skeletal 
muscle (Shier, 2009).  
 
  
3 
 
FIGURE 1: DIAGRAM INDICATING THE STRUCTURE OF SKELETAL MUSCLE (SHIER, 2009) 
 
2.1.2 MYOCYTE STRUCTURE AND FUNCTION 
Each myofibril, or myocyte, contains several sarcomeres. One sarcomere represents 
one functional unit. Each sarcomere contains several actin (thin) and myosin (thick) filaments. 
These filaments are stimulated when calcium ions are transported to them from the 
sarcoplasmic reticulum (SR). The SR surrounds each of the myofibrils and transmits an 
electrical signal, which is created at the neuromuscular junction. Once stimulated, the myosin 
heads attach to the actin and slide over one another, known as the Sliding Filament Theory. 
This shortens the sarcomere and, as a result, contracts the muscle (Shier, 2009). 
2.2 SKELETAL MUSCLE REGENERATION 
 After injury, skeletal muscle is unique in the sense that it has the ability to regain 
complete functionality provided that the volumetric tissue loss from the injury is not too high 
(Collins, 2006). Regeneration relies on primary muscle satellite cells throughout the healing 
process which consists of three phases: 1) Inflammation, 2) Tissue formation, and 3) Tissue 
remodeling.  
 Inflammation is the first phase of skeletal muscle regeneration. This phase begins 
immediately after the injury followed by the process of necrosis of the injured myofibers and an 
inflammatory response (Turner and Badylak, 2012). When the skeletal muscle is initially injured, 
the myofibers rupture and release proteases that then lead to rapid degradation of the fibers. In 
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order to concentrate the proteases and isolate the damaged region, a cytoskeleton is created.  
When the proteases are released into the wound site, macrophages are signaled which induces 
the inflammatory response. Macrophages are important in skeletal muscle regeneration 
because they are responsible for the inflammatory response and they also help to support cell 
proliferation later in the healing process (Brunelli and Rovere-Querini, 2008). As the 
macrophages flood the site of the ruptured myofibers, they interact with the nearby satellite cells 
to promote chemotaxis, or movement of the satellite cells from a region of high cell 
concentration to low concentration. The macrophages also release TNF-α and IL-1β. These 
increase phagocytosis of the damaged tissue (Grefte, 2007). After 24 hours, another group of 
macrophages begin secreting anti-inflammatory factors and cytokines that increase cell 
proliferation and begin the process of tissue reformation. 
 Tissue formation consists of satellite cell proliferation and differentiation, which leads to 
the formation of new skeletal muscle tissue. Figure 2 shows this process. 
 
FIGURE 2: SKELETAL MUSCLE REGENERATION (SHI AND GARRY, 2006) 
  
Satellite cells are quiescent when residing between the basal lamina and sarcolemma. 
There is limited gene expression, however this can become activated by trauma or myo-
degenerative disease (Le Grand and Rudnicki, 2007). In looking at the figure above, one can 
observe that upon the arrival of the second macrophage population at the end of the 
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inflammatory phase, chemotactic factors, such as growth factors FGF, HGF, IGF-I, IGF-II, TFG-
β, and IL-6 (Charge and Rudnicki, 2004), are released in order to attract quiescent satellite cells 
if the basal lamina has been damaged (Ciciliot and Schiaffino, 2010).  
During activation, the cycling myoblasts start to co-express the paired-box transcription 
factors Pax7 and Pax3, and the myogenic regulator factors Myf5 and MyoD. These myoblasts 
will continue to divide and differentiate to form myocytes, leading to the downregulation of Pax7 
and expression of myogenin. The differentiated myocytes fuse together to form multinucleated 
myofibers. Protein markers can be labeled and play an important role in satellite cell 
development, as it is needed for the differentiation of skeletal myoblasts. Myogenin is also 
important for the formation of myotubes and fibers as it downregulates the Pax7 gene, which is 
responsible for continuing myoblast growth and delaying differentiation (Le Grand and Rudnicki, 
2007). When myoblasts differentiate, they express myosin protein. A diagram of satellite cell 
development into myofibers, as well as the factors and proteins present during these phases 
can be seen in Figure 3. These factors and proteins are important as they may have the 
potential to be used in assays as an early marker for the development of myofibers.  
 
FIGURE 3: FLOWCHART OF HUMAN MYOGENESIS WITH RESPECTIVE EXPRESSED PROTEINS (LE 
GRAND AND RUDNICKI, 2007) 
During the healing process, satellite cells from nearby muscle fibers migrate to the 
damaged tissue where they proliferate in order to rapidly repopulate the myofiber. Towards the 
end of the proliferation cycle, the satellite cells either differentiate into myoblasts or they return 
the quiescent state for future regeneration purposes. The cells that differentiate either bind 
together to form new myofibers or fuse to damaged myofibers to help the repairing process 
(Brunelli and Rovere-Querini, 2008). This phase generally occurs 24 hours after the initial injury. 
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 Tissue remodeling is the final phase of skeletal regeneration. The newly formed skeletal 
myofibers are not completely matured at this point and therefore need to enter the remodeling 
phase. This process consists of revascularization, reinnervation, and alignment so that the new 
muscle can fully integrate with the surrounding muscle (Turner and Badylak, 2012). 
 In order to reestablish the supply of nutrients and oxygen to the new tissue, 
revascularization must occur early in the process otherwise the new myofibers cannot survive. 
For survival, myoblasts need to be within approximately 150 µm of a blood supply. This is the 
maximum thickness that the nutrients and oxygen can diffuse through. Once the vascular 
connection is established, a neural connection, or reinnervation, must occur. These 
neuromuscular junctions are responsible for the uniform contraction of a muscle. If connections 
are not made as the tissue is formed or soon after, the muscle will develop atrophy, resulting in 
further injury. The last phase of remodeling is the alignment of the myofibers in order to fully 
integrate them into the preexisting muscle. First, the basal lamina is repaired. Next, the 
myofibroblasts replace the temporary matrix created during the tissue formation phase (Turner 
and Badylak, 2012). The myofibroblasts allow for complete maturation of the newly remodeled 
tissue, thus creating a fully functional regenerated muscle tissue.  
 For small-scale injuries, fibroblasts infiltrate the wound site, and deposit collagen to 
create scar tissue that bridges the gap between the functional myofibers. For these injuries, the 
collagen aids in promoting muscle formation. However, for larger scale muscle injuries, there is 
an overwhelming fibrotic response. Fibroblasts quickly deposit collagen faster than myogenesis 
can occur. This causes scar tissue to form dense caps over the muscle fibers, preventing any 
myoblasts from fusing to the tissue to close the wound. This lack in fusion between the 
myoblasts and existing muscle results in volumetric muscle loss occurs (Turner and Badylak, 
2012).  
2.3 ENGINEERING SKELETAL MUSCLE TISSUE 
 Skeletal muscle tissue engineering could provide treatment to muscle diseases including 
muscular dystrophy and spinal muscular atrophy, as well as situations in which there is a loss of 
muscle tissue, including traumatic injuries. In order to engineer skeletal muscle tissue, several 
requirements must be met. First, the myofibrils must be in parallel alignment with the myosin 
and actin filaments. There also must be acetylcholine receptors within the tissue, which assists 
in creating forces within the muscle. In addition, there should be an intracellular calcium storage, 
which aids in muscle contraction (Liao, 2009). If this tissue is to be implanted into the body, it 
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must be biocompatible, integrate into the native tissue, and be vascularized and innervated to 
ensure viability (Vandenburgh, 2002).  
 In order to be used as a model, there needs to be a standardized, easy, reproducible, 
low-cost, and fast method to culture the cells. It also must be engineered using recognized cell 
lines, such as human primary satellite cells or C2C12s, to control the variability and mutations of 
testing gene function. In order to test the function of the tissue, it needs to be able to respond to 
mechanical and electrical stimuli (Khodabukus, 2007). Mechanical stimulation through applying 
stretch forces and pressure during myogenesis on the tissue influences gene expression, 
protein synthesis, and RNA/DNA content. It also promotes the parallel alignment within the 
myotubes needed. To develop more functional skeletal tissue and a higher differentiated 
population, electrical stimulation is used to imitate nerve stimulation during myogenesis. A static 
magnetic field can also aid in muscle differentiation and help the parallel orientation within the 
myotubes as well (Liao, 2009). 
There are two common practices used to engineer skeletal muscle tissue. The first 
method, in vitro cell therapy, involves taking a biopsy to obtain the muscle cells, and then 
culturing them in a bioreactor. Upon differentiation, these cells are then reimplanted into the 
body. The other method, in vivo cell therapy, involves the cells to be obtained and grown in 
vitro. These cells are then seeded onto a transport matrix, where they are then implanted into 
the body, where they eventually differentiate into myotubes (Liao, 2009). 
2.4 CLINICAL NEED 
Injuries to the musculoskeletal system are common, and often arise from sports/exercise-
induced injuries, combat trauma, or motor vehicle accidents. About 10%-55% of sustained 
sports injuries are muscle related, and are primarily contusions or strains. While these injuries 
are common and can lead to volumetric muscle loss, there are few clinical studies that have 
been conducted to treat this (Turner and Badylak, 2012).  
For smaller scale injuries (tears, lacerations, contusions), there is not a significant loss of 
tissue. This is primarily due to the progenitor satellite cells found in the muscle tissue. The more 
severe the injury, however, the more difficult it is for the muscle to repair itself. If more than 20% 
of the muscle tissue is lost or damaged, the tissue will not be able to regenerate, and instead 
non-functional scar tissue will form (Turner and Badylak, 2012)..  
The current standard of care is to use a graft of vascularized tissue to aid in the 
restoration of the tissue. Surgery can also aid in restoring function, however the tissue is not 
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regenerated and it may lead to alterations in the biomechanics of the implant site, as well as the 
donor site (Turner and Badylak, 2012). 
A tissue engineering approach of using satellite cells to aid in regeneration could offer a 
solution to volumetric muscle loss. Currently, the Page Lab has been researching methods to 
combat this problem using autologous cell therapy. This research includes implanting cell-
loaded microthread bundles into a skeletal muscle wound site. It has been found that this aids in 
the reformation of functional skeletal muscle and reduces the amount of scar tissue and 
collagen present in the wound (Page et al., 2011).  
While this method has been successful when tested on a mouse, there are in vitro 
limitations. In order to treat a human-sized wound, the amount of cells needed must be scaled 
up. Therefore, an abundance of cells need to be available. Unfortunately, the myogenic 
potential of human primary satellite cells is lost with each passage. In order to use this type of 
cell therapy for humans, a process to optimize the cellular growth and expansion must be 
defined.  
2.5 CELL CULTURE MEDIUM AND ENVIRONMENT 
 When culturing cells in a controlled environment, there are several factors that can 
directly affect their growth. It is important to understand that each of these components can 
work together to best mimic an in vivo like environment, making the cell culture as close to 
normal human cells as possible. The following sections discuss different medium components 
and ways to create an in vitro cell culture environment.  
2.5.1 RECREATING SKELETAL MUSCLE TISSUE ENVIRONMENT 
In order to successfully grow skeletal muscle cells in culture, similar biological conditions 
must be mimicked. Cells are grown in incubators that are kept at 37°C which is the same 
temperature of the human body.  Further, the amount of oxygen and carbon dioxide in the cell 
culture system is also monitored. Too much or too little of these compounds could result in cell 
death. Generally, cells are grown in 15-20% O2 and 5-10% CO2 (Wolf, 2010). It is also important 
to monitor the pH of the cell culture as it directly relates to how the cells are growing. If the pH is 
too acidic, it can be assumed that a lot of cell growth has occurred resulting in cell waste, 
making the medium acidic and change colors. A pH that is too high or too low can directly affect 
the cells in the culture and could potentially damage them (Whitefleet-Smith, 2012).  
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2.5.2 BASIC MEDIUM COMPONENTS 
 When culturing cells it is essential that they obtain the proper amount of nutrients to 
support optimal cell growth, which is dictated by the medium used. Thus, it is vital that the 
medium has the proper components. Many basic elements and ions can be found in most 
mediums to support the cells. These include sodium, potassium, calcium, magnesium, chloride, 
phosphorus, iron, and zinc as well as some vitamins and amino acids. These are present to 
allow the cells to perform normal functions. In order to promote cell growth, other components 
such as glucose, antibiotics, and serum are added to the medium. Glucose provides a sugar 
source for the cells while the antibiotics help to prevent any contaminations that may occur 
throughout the cell culture process. Lastly, serum is added to the medium as it contains a lot of 
valuable properties. In general, serum has a lot of nutrients and various growth promoting 
components and can buffer toxic substances in the medium to neutralize them. Further, serum 
contains a large amount of peptide hormones and growth factors that greatly promote healthy 
cell growth (Wolf, 2010).  
2.5.3 GROWTH FACTORS 
 There are four different growth factors that will be considered in this study: Epidermal 
Growth Factor (EGF), Fibroblast Growth Factor (FGF), Hepatocyte Growth Factor (HGF) and 
Insulin-like Growth Factor (IGF). Each one of these growth factors plays an important role in cell 
growth and differentiation. EGF has been known to stimulate RNA, DNA and protein synthesis, 
as well as increase the cell uptake of nutrients, within mammalian skin cells (King, 1985). FGF 
has the unique role of regulating cell migration, differentiation and proliferation (Ornitz, 2001). 
On the other hand, HGF regulates cell growth and cell movement (HGF, 2012). Lastly, IGF 
maintains and regulates the normal physiology within an organism and at the cellular level; it 
promotes cell proliferation and prevents apoptosis, also known as cell death (Clemmons, 2012). 
These mitogens can be used to aid in the growth of human primary satellite cells, and are 
currently being used in the Page Lab.   
2.6 TESTS FOR MYOCYTE CULTURE 
In cell culture there is a need to observe how cells are growing and behaving in their 
environment. Being able to see how the cells react to different induced changes is crucial to 
further research as well as understanding their behavior. There are several analytical 
techniques that can be used to observe how cells are growing and developing in a culture. The 
following is an overview of the main tests that will be utilized throughout the project.  
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2.6.1 BROMODEOXYURIDINE (BRDU) CELL PROLIFERATION ASSAY 
The ability to see if cells are dividing is an essential cell culture technique that allows for 
the observation of how well cells are dividing. By labeling DNA that is synthesized, one can 
easily detect the formation of new cells. The BrdU Cell Proliferation Assay uses 5-bromo-
2’deoxyuridine (BrdU) to label newly synthesized DNA. This is achieved by adding BrdU to the 
cell culture and allowing it to incorporate into DNA as the cells go through mitosis as BrdU is a 
nucleoside analogue for thymidine. Once cells undergo the S-phase of the cell cylce, the BrdU 
will be incorporated into the new cell allowing it to be detected. Once cells have been cultured 
for a defined time period, immunocytochemistry procedures can be completed to highlight the 
new cells. First, they are fixed and a primary antibody is added. This primary antibody, also 
known as Anti-BrdU antibody, binds to the BrdU that is now found in the DNA. Next, a 
secondary fluorescent antibody is added and correspondingly binds to the primary antibody. 
Finally, cells are stained with a Hoechst dye to identify the nuclei present. After this is 
completed, the cells that have divided will now fluoresce as seen in Figure 4B. Therefore, the 
cells that have not divided and do not contain BrdU will not fluoresce when observed under a 
fluorescence microscope. The total cell population can be seen in Figure 4A. Further, this assay 
easily allows for the observation of how cells are behaving and dividing in different 
environments (Ambady, 2012b).  
 
FIGURE 4: A) LIVE C2C12 CELLS STAINED WITH HOECHST AT 20X MAGNIFICATION. B) 
PROLIFERATING C2C12 CELLS WITH SECONDARY FLUORESCENCE ANTIBODY AT 20X 
MAGNIFICATION (OBER, 2012) 
2.6.2 IMMUNOCYTOCHEMISTRY (ICC)  
Similar to the BrdU assay previously described, immunocytochemistry (ICC) assays can 
also be used to target any marker in the cell as it goes through differentiation. Specifically, 
antibodies can be used to target myosin heavy chain. This technique detects myosin in the cells 
present. Myosin is a result from cells successfully forming differentiated myotubes. These are 
known to be signs of muscle cell development. In order to detect the myosin, a similar 
procedure as the BrdU assay is applied. This procedure labels the myosin by using a primary 
A)              B)    
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antibody to bind to the myosin. Once the primary antibody is added, the secondary fluorescent 
antibody is added and correspondingly binds to the primary antibody. Once this is complete, the 
cells that express myosin will fluoresce when placed under a fluorescence microscope, as seen 
in Figure 5. This assay allows for the observation of the development of muscle cells, which can 
be extremely useful when trying to culture a single muscle cell to perform quantitative analysis 
on (Ambady, 2012c).  
 
FIGURE 5: A) MUSCLE CELLS STAINED WITH HOECHST AT 10X MAGNIFICATION. B) C2C12 CELLS 
WITH SECONDARY FLURESCENCE ANTIBODY AT 40X MAGNIFICATION (OBER, 2012)  
2.7 NON-ADHERENT CELLS 
When cells are cultured using a specific combination of growth factors, there is a 
population of adherent cells, in which the cells attach to the surface of the flask, and non-
adherent cells, in which the cells remain in suspension. As the cells start to replicate, there is a 
large amount of these non-adherent cells. In many cell culture studies, the non-adherent cell 
population is completely removed when the medium is changed in the culture. Only a few of 
these cells, however, are dead. As the non-adherent cells are flushed out with each media 
change, there is little research done on the efficacy of these cells, and whether or not they have 
the capacity to produce skeletal muscle tissue. Overall, this loss of cells can contribute to a 
lesser amount of cells obtained in the culture (Personal Communication, September 4, 2012). 
However, Gharaibeh et al. have developed a protocol to obtain skeletal muscle cells that 
adhere rapidly or slowly from murine skeletal muscle. This preplating technique involves 
isolating the skeletal muscle cells based on their adhesion characteristics. The cells that adhere 
rapidly consist of fibroblast cells. After two hours, the non-adherent cells are passaged and re-
plated into a new flask. This process is repeated four more times over the following four days to 
produce six different cell populations. The slowly adhering cells contain muscle-derived stem 
cells, which can be used to engineer skeletal muscle tissue (Gharaibeh, 2008). 
A)              B)    
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In the Page Lab, when feeding cells, they are placed into a tube, centrifuged, and half of 
the medium is aspirated. Following this, 4 mL of fresh medium is inserted, re-suspended, and 
then fed into the flask. After a couple of days when cells need to be subcultured, the entire 
culture is trypsinized and counted. In the past, the Page Lab would take the non-adherent cells 
only and passage them forward. What they discovered is that these cells are somewhat 
consistent with a highly mitogenic population. If just the adherent population is put into a culture 
with the same medium for growth, another non-adherent population will grow. Overall, this is 
evidence that these cells are highly myogenic, and when these cells are discarded the viability 
is decreased (Personal Communication, September 4, 2012). 
2.8 COST ANALYSIS 
As discussed earlier, medium is an essential part of cell culture. The components of the 
medium provide the necessary nutrients that aid in cell growth. In addition to the base medium 
and serum, growth factors are often supplemented to the medium in order to enhance the 
proliferative ability of human primary satellite skeletal muscle cells. While these components 
may provide added benefits to the cell culture, they can be costly. Below in Table 1, is a 
breakdown of the cost of the current medium composition that is used in the Page Lab to grow 
these cells. Based on the cost from various companies, the cost to make 50mL of medium is 
$6.77. 
TABLE 1: COST BREAKDOWN OF EACH MEDIUM COMPONENT, AND CALCULATED COST TO MAKE 
50 ML OF MEDIUM.  
Component Amount/50mL 
Commercial Price Price/50mL of 
Medium Amount Price 
DMEM 25 mL 6 X 500 mL $115.46 $0.96 
F12 18 mL 6 X 500 mL $98.67 $0.59 
FCIII 5 mL 12 X 500 mL $153.42 $0.13 
Glutamine 0.02922 g 100 g $87.92 $0.03 
Growth Factors     
FGF2 (4ng/ml) 20 μL 10ug solid $80.00 $1.60 
HGF (2.5ng/ml) 12.5 μL 10ug solid $195.00 $2.44 
IGF (5.0ng/ml) 5 μL 50ug solid $195.00 $0.98 
EGF (10ng/ml) 2.5 μL 500ug solid $195.00 $0.05 
 Total Cost: $6.77 
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3. PROJECT STRATEGY 
 This chapter outlines the project strategy used to develop and define the project, based 
on the engineering design process. The team identified and prioritized the project’s objectives, 
constraints, and revised the client statement. Through this process, the team was able to better 
understand the needs of the client versus their desires to ultimately outline a final strategy. 
3.1. INITIAL CLIENT STATEMENT 
 Before the project was able to advance, the design team had to understand and 
decipher between the client’s desires and needs. The client statement received was broad and 
not focused on a specific problem; therefore, it required revision. The text below is the initial 
client statement provided by Dr. Raymond Page: 
“Currently, the laboratory uses extruded fibrin microthreads with human skeletal muscle 
derived cells seeded onto the surface and transplanted into SCID mouse skeletal muscle 
injury models to study the effect of various cell derivation and culture methods on 
functional tissue regeneration.  One of the limitations in primary human skeletal satellite 
cell and myoblast culture in vitro is the loss of myogenic potential with each subsequent 
passage.  Some of this loss may be attributed to contamination of fibroblasts in the 
culture, and therefore selective amplification of the fibroblasts over the myoblasts, given 
the culture conditions employed.  The laboratory has recently discovered a culture 
system based factors and selective cell adhesion characteristics that enable the 
propagation of mostly myogenic cells which on specific growth are capable of 
differentiating into myocytes upon removal of mitogens from the culture medium.   
 
In order to apply this technology at large and economical scale, the detailed growth 
factor dependent and substrate physical/biosignaling properties must be defined, and 
optimized.  The goals of this project are: 
 
• Design an in vitro cell culture system that selectively amplifies myogenic cells by 
employing combinations of differential adhesion, selective mitogenic (growth 
factor) stimulation and controlling ambient oxygen.  
• Determine the growth kinetics and cell purity, and differentiation potential of the 
myogenic cell population with increased time in vitro according to individual 
system design parameters.  The myogenic potential (measured by the fusion 
index) for the cells at the end of the culture period must be at least 30%. 
• Employ individual parameter optimization results to engineer, build, and test a 
final ex vivo myogenic cell expansion system.   
• Extrapolate (scale up) prototype system to enable replacement of 20 ml of 
muscle tissue from cell derived from a 200 µl skeletal muscle biopsy.” 
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3.2. OBJECTIVES AND FUNCTIONS 
 After interviewing the client, the team was able to construct a list of objectives and 
functions. This kept the team on task and allowed them to focus on the realistic goals.  
3.2.1. OBJECTIVES 
Objectives are goals and sub-goals that should be sought out in the final design. They 
are measureable and defined. At the end, they can be achieved in the expected time frame. 
After developing a list of objectives, the group met with the client to be sure the list of objectives 
highlighted the key tasks or needs of the problem.  
An objectives tree was then created in order to organize the objectives. Higher order 
objectives are located further left while sub-objectives are located further right. As shown in the 
objectives tree in Figure 6, this project has three main objectives: commercializable, optimize 
non-adherent cell population, and user friendly.  
 
FIGURE 6: OBJECTIVES TREE 
The process needs to have commercial potential. Specifically, the design needs to be 
easy to scale up. The team is performing the tests and assays on a small scale; however, to 
implement this process, it needs to be used on a larger scale. First, the process should be made 
from common supplies, or anything that can be easily purchased or found in a lab. This will also 
Optimize Satellite Cell 
Propagation and 
Myogenic Potential 
Commercializable 
Easy to scale up 
Uses common supplies/parts 
Repeatable process 
Cost effective 
Optimize non-adherent 
cell population 
User friendly 
Sterilizable 
Removable 
Portable 
Easy to Repair 
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help to keep the product inexpensive. In addition, the process must be repeatable to allow for 
consistent results to be obtained. The final product must also be cost effective.  
The developed product also needs to optimize the non-adherent cell population. There 
are multiple ways to accomplish this goal including, but not limited to, changing medium 
components such as growth factors and medium nutrients.   
In order for the product to be user friendly, it needs to be easy to integrate into a typical 
cell culture lab setting. One of the key aspects to consider is sterilization, because when 
culturing cells, bacteria can easily contaminate and destroy cell life. Therefore, the limitations of 
sterilization tools like an autoclave must be considered. In addition, the design must follow 
aseptic techniques. Similarly, the device needs to have the capability of being moved from one 
setting to another, thus it should be easily removable and portable. In the event that the product 
breaks, the user should be able to easily repair it.  
 From the list of objectives, the team was able to create a pairwise comparison chart in 
order to rank the importance of each objective. The objectives that are more important receive a 
score of 1, while if they are of equal importance, each receives a score of 0.5.  Overall, the 
objectives are ranked based their total score. The team’s completed pairwise comparison chart 
is shown in Table 2 below. As observed, the most important objectives are for the process to be 
sterilizable and to optimize the non-adherent cell population. Other important objectives include 
ensuring the process is cost-effective, easy to scale up, and repeatable.  
 
TABLE 2: PAIRWISE COMPARISON CHART  
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3.2.2. CONSTRAINTS 
If the process does not meet the prescribed limitations, the process fails. Using client interviews 
and research, the team was able to create a list of constraints, shown below. 
 The entire project must remain under the budget of $524. 
 The entire project must be completed in 28 weeks. 
 The medium components must be compatible with the cells being used. 
 The team is limited to human primary satellite cells (Page et al., 2011). 
 The final product must be safe for the user. 
 The final product must be sterilizable or create a sterile environment to inhibit cell 
contamination. 
 The myogenic potential for the cells at the end of the culture period must be at least 30% 
(Page et al., 2011). 
 
3.3. REVISED CLIENT STATEMENT 
 After interviewing the client and identifying the project’s objectives and functions, the 
team was able to refine the initial client statement to better portray the client’s needs. The team 
first removed unnecessary information and added in specific objectives to better define the 
scope of the project. The team identified that the culturing of the non-adherent cell population 
was the main focus. The text below is the revised client statement: 
• “Research, design, and optimize a process for non-adherent cell growth and enable the 
production of myogenic competent cells. Improve the cell culture process through 
optimization of the medium components necessary for myogenic competent cells. 
Return a final, tested and verified design. Conduct a cost-benefit analysis of the final 
design.” 
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4. ALTERNATIVE DESIGNS 
The following outlines the team’s various method options of achieving the project goal to 
improve the myogenic potential and growth of human primary satellite cells. In addition to the 
previously listed objectives and constraints, the team brainstormed various alternative designs 
to complete the project. After conducting a feasibility test, a final alternative design was chosen, 
and a list of functions and specifications were developed. Upon selecting the final design, a the 
team determined the project approach.  
4.1. DESIGN ALTERNATIVES 
After brainstorming, the team was able to develop four design alternatives that could be 
used in this project. Each design has unique characteristics, which are described below. 
4.1.1. CELL CULTURE FILTER PLATE 
The first alternative design was a Cell Culture Filter Plate. Based on the Filter Plate from 
Millipore, the purpose of this design is to improve the cell culturing process and to retain the 
non-adherent cells (EMD Millipore, 2012). As shown in Figure 7, the plate allows for the medium 
to be vacuumed out, while keeping all the adherent and non-adherent cells. Each of the 24-well 
receivers have their own port for medium distribution. The teardrop well design removes the 
chance of air bubbles, while the raised edges improve the sealing of the well to decrease 
contamination (EMD Millipore, 2012). While the current design is a 24-well plate, the plate can 
be reverse-engineered to be a single well plate. The disadvantages of this design include that it 
does not remove human error during medium changes and cell passaging and the plates are 
also too expensive for the budget available to the team.  
 
FIGURE 7: CELL CULTURE FILTER PLATE (EMD MILLIPORE, 2012) 
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4.1.2. AUTOMATED HANDS FREE MEDIUM CHANGE 
The second design utilizes gravity and a series of valves to move and measure medium 
throughout a culture system. The purpose of this design is to not have any human interaction 
during the cell culture process. Instead, a Programmed Logic Controller (PLC) operates the 
system. This is connected to three solenoid valves and one level sensor. The PLC can be 
programmed to turn these valves on or off after a certain time interval has passed. This allows 
for the culture system to be continuously cultured without the need of personnel in the lab. By 
having an automated system, the process is repeatable and the risk for human error is also 
greatly decreased. The only human interaction in this design is placing medium in the initial 
medium reservoir. After the programmed time span, the first valve will open and allow medium 
to flow into the chamber, which measures the amount of medium. When the fluid level reaches 
the level sensor, a signal is sent to the PLC and the first valve is shut off. Once the medium is 
measured, the second valve will open and medium will drain into the culture dish. At this point, 
the medium could be in the cell culture dish for an extended amount of time. However, once the 
PLC allows the next valve to open, the medium, which contains the non-adherent cell population 
will drain and be placed into either another cell culture dish or a waste container. A preliminary 
design of this can be seen in Figure 8 below.  
 
FIGURE 8: CAD DESIGN OF AUTOMATED HANDS FREE MEDIUM CHANGE DESIGN 
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4.1.3. CONTINUOUS MEDIUM FLOW  
The third design alternative uses an ebb and flow/hydroponics based design. This 
design allows for a continuous fresh flow of medium throughout the system. In this system, the 
cells are plated onto a Petri dish and protected with a semi-permeable membrane that allows 
the medium to flow through, but keeps the cells in the plate. The dishes are placed in a closed 
container, which houses the medium and an overflow tube. When there is too much medium in 
the container, it goes through the overflow tube and into another container that just houses the 
medium. Using a pump, this medium is then pumped back to the upper container, providing a 
continuous cyclic flow of medium. With this design, the medium in the bottom container can 
easily be changed by removing this container and adding fresh medium. One of the anticipated 
challenges that this design faces is making sure that all of the medium (growth factors, 
antibiotics, etc.) flows through each Petri dish, instead of a direct path to the exit. One way to 
counter this is to make the upper container more narrow, and only allowing one row of Petri 
dishes, so the medium flows in one straight line. An initial sketch of this design alternative can 
be seen below in Figure 9. 
 
FIGURE 9: CAD DESIGN OF CONTINUOUS MEDIUM FLOW DESIGN 
4.1.4. PROCESS ENGINEERING DESIGN 
The fourth design alternative consists of analyzing the current process used to culture 
human primary satellite cells and highlight areas for improvement. Through this, the team 
identified that the culturing medium, primarily the growth factors within this medium, had the 
greatest effect on cell propagation. By modifying the medium through growth factor levels, the 
cells should reflect these changes in the cell growth and myogenic potential. The growth factor 
concentrations were modified by isolating each growth factor, removing one or two of the growth 
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factors, and then increasing and decreasing individual growth factor concentrations. The 
challenge of this method is that until testing, the team is not sure of how the addition or 
subtraction of growth factors may affect the growth or myogenic potential of the cells.  
4.2. FEASIBILITY TESTING 
Before determining a final design, the team needed to determine the feasibility of each of 
the aforementioned design alternatives. First, the cell culture filter plate design does not allow 
for easy transfer into another culture dish, nor does it reduce human error. This device is also 
not reasonably priced and for these reasons the team will not be moving forward with this 
design alternative. Next the continuous medium flow device was ruled out. It would be difficult to 
ensure that each individual plate will receive equivalent medium components. A membrane that 
would allow for medium to pass through feeding both the adherent and non-adherent 
populations would be difficult to fabricate and would not be made from common parts, which is 
an objective. Of the 3 device designs the automated hands free device seemed to be the most 
promising. With the ability to reduce human error through automated cell passaging, it also 
allows for co-culturing of both the adherent and non-adherent population. However a device 
such as this could be bulky and cumbersome. The logistics behind building a device of this 
magnitude would also be likely to expand outside the team’s budget. 
For the reasons listed above the team decided it would be best to move forward with the 
process engineering design. This is the simplest design and would be easiest to incorporate into 
the current laboratory techniques and tasks.  It was determined that it was most beneficial for 
the client to focus on the process being used to culture these cells and optimize it. This design 
allows the co-culture of the adherent and non-adherent populations as well as the ability to 
isolate important factors that significantly impact the growth and myogenic potential.   
 
4.3. FUNCTIONS AND SPECIFICATIONS 
Through interviewing the client and brainstorming amongst the team, a list of functions 
and specifications were developed to aid in designing various options.  
4.3.1. FUNCTIONS 
The group created a functions-means chart shown in Table 3 below. The functions-
means chart is a tool that compared the different options to satisfy the function. These means 
further allowed the team to brainstorm design alternatives that meet the needs.  
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TABLE 3: FUNCTIONS-MEANS CHART 
Functions Means 
Optimize 
myogenic 
potential 
Alter growth 
factor 
concentrations 
Alter 
serum to 
medium 
ratio 
Alter 
passage 
times 
   
Optimize 
non-
adherent 
cell growth 
Alter growth 
factor 
concentrations 
Alter 
serum to 
medium 
ratio 
Alter 
passage 
times 
Alter 
seeding 
density 
Antibiotics Glutamine 
 
From the table above, the team identified two functions. The process must optimize the 
myogenic potential and non-adherent cellular propagation. When culturing human primary 
satellite cells, it is observed that there are both adherent and non-adherent cells. It is normally 
thought that the non-adherent cells are dead. However, in this culture the non-adherent cells are 
alive and have been shown to have a high potential for differentiation into the skeletal muscle 
cells. Having a high myogenic potential is essential. If cells do not exhibit 30% myogenic 
potential then they will be ineffective when used for cell therapy. 
In addition to enhancing the myogenic potential, it is important to maintain and optimize 
the living cell population. Since cell growth can be affected by different medium components, 
the team must determine the best combination. Further, the team will determine the ideal 
passaging time and seeding density that will provide the optimized cell population. As it is 
thought that the non-adherent cell population is correlated to a high myogenic potential, this cell 
population will be optimized. For these reasons, the team must optimize the myogenic potential 
and cellular growth of the cultures. 
Normally, when a cell culture is passaged, the cell population is split and divided. Once 
the cells are split, they are given new medium to provide nutrients for the culture. The team will 
continue to work with and passage the non-adherent cell population in order to optimize the 
myogenic potential in the total cell population. Thus, a cell population will develop into adherent 
skeletal muscle cells. 
4.3.2. SPECIFICATIONS 
A specification is a detailed description of a design. The following is a listing and 
explanation of the specifications the team was able to derive.  
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• Medium components: 
o Proliferation Medium: A 60/40 ratio of Dulbecco’s Modified Eagle Media 
(DMEM) (Corning) and F12 (Corning) respectively is currently used as the 
base medium for culturing human primary satellite skeletal muscle cells 
(Page et al., 2011). DMEM is the most common medium used in cell culture. 
It is also inexpensive, allowing the team to remain under budget (Whitefleet-
Smith, 2011). This medium is supplemented with 10% fetal clone III serum 
(FCIII) (Hyclone), 4mM glutamine (Cellgro), 1X penicillin streptomycin (EMD), 
and a proprietary cocktail of growth factors. Fetal clone III serum (FCIII) 
contains nutrients and natural growth factors that aid in the growth of healthy 
cells (Whitefleet-Smith, 2011). Glutamine provides sugar for the cell to use to 
allow it to perform its normal functions as well as glycolysis (Whitefleet-Smith, 
2011). Antibiotics, specifically penicillin/streptomycin will be used to help 
reduce the chance of any bacterial contamination that arises due to human 
error (Whitefleet-Smith, 2011). Four growth factors (FGF2, EGF, IGF, and 
HGF) will be used in different concentrations to understand their effect on the 
proliferation rate and myogenic potential of the cells. These results will be 
used to understand the minimum amount of growth factors that return the 
optimal results and reduce cost. Specifically, FGF2 is used to produce a non-
adherent cell population (Personal Communication, September 4, 2012).  
o Differentiation Medium: Similar to the proliferation medium, a 60/40 ratio of 
DMEM and F12 will be used as the base medium. This medium will be 
supplemented with 2% horse serum (Hyclone), 1% ITS (Hyclone), 4 mM 
Glutamine, and 1X penicillin streptomycin. The primary difference between 
this medium and proliferation medium is that it lacks mitogens, and therefore 
induces differentiation of the myoblasts. A detailed recipe for each of these 
mediums can be found in Appendix B.   
• Cells: 
o Human primary satellite cells will be used, as these are the type of cells that 
are being used for autologous cell therapy to reduce volumetric muscle loss. 
4.3 PROJECT APPROACH 
The team developed a four-step process to complete this project. These steps included 
cell culturing, preliminary testing, assessing the proliferation rate and myogenic potential, and 
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developing a cost-benefit analysis of the final design. As seen in Appendix A, a Gantt chart was 
created to plan and organize the steps necessary to complete the project.  
4.3.1  CELL CULTURE 
The first part of the projected included getting a greater understanding of the cell culture 
process that is currently used in the Page Lab. To do this, members of the team toured the 
laboratory and learned how the current process is carried out and identified areas of 
improvement. The team also obtained the medium recipes for proliferation and differentiation of 
the cells, which can be found in Appendix B.  
Upon learning the proper cell culture techniques, the team began culturing human 
primary satellite cells by seeding 500,000 cells into T75 culture vessels. The cells were cultured 
until they became 60% confluent. If any contamination was observed in the culture, the plates 
were immediately discarded. After thawing, the cells underwent one successful passage before 
any plating for testing began. The Cell Culture Protocols used in this project can be found in 
Appendix C. 
4.3.2 PRELIMINARY TESTING 
Growth factors play a key role in the growth of the cells; however their exact contribution 
on cell growth and myogenic potential still needed to be understood. The team derived 23 
different medium treatments to test through the removal of one, two or three growth factors, or 
by increasing or decreasing the concentration of single growth factor. The cells were seeded 
onto 24-well plates using the different treatment mediums and then assessed by counting the 
adherent and non-adherent cells. In addition, a BrdU assay and an ICC for myosin heavy chain 
were conducted to determine the proliferation rate and the percent differentiation into myotubes. 
After observing the results from these tests, the medium concentrations that provided the 
optimal proliferation of non-adherent cells and highest differentiation percentage were used for 
further testing.  
4.3.3 TESTING FOR PROLIFERATION RATE AND MYOGENIC POTENTIAL 
In order to determine which medium would yield the highest proliferation and amount of 
differentiated cells, ICCs for BrdU and myosin heavy chain were repeated for validation. A cell 
count was also conducted to determine the total cell count and the percent of non-adherent 
cells. Since the non-adherent cell population is believed to be more myogenic as well as 
providing other assets during culture, it is important to find a medium that contains a high 
percentage on non-adherent cells. From these three sets of data the team narrowed the 
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medium down again and tested for myogenic potential.  
An ICC assay for myogenic potential was conducted on differentiated muscle cells. Cells 
were grown in the previously determined growth factor medium concentrations, switched to 
differentiation medium, and then tested. The mirror cultures were stained for both MyoD and 
myosin heavy chain. Cells were then determined to be differentiated or non-differentiated, to be 
part of a multinucleated myotube, or to contain MyoD. The MyoD to myosin heavy chain ratio 
provides data to determine if MyoD can be used as an early marker for myogenic potential. In 
addition, fusion index calculations were completed to determine which treatment medium 
contains the greatest percentage of myogenic potential.   
4.3.4 COST-BENEFIT ANALYSIS 
Finally, a cost-benefit analysis was conducted to compare the costs of the current 
medium against the final medium composition. The cost to grow the amount of cells to treat a 15 
cubic cm wound was calculated, and the amount of medium to grow these cells was 
determined. This was used to decide if the chosen treatment medium provided the added 
proliferative and myogenic benefits necessary. The cost change was then used to determine if 
the added benefits from the medium outweighed the additional costs, or potential reduced cost.  
4.4. PROCESS ENGINEERING APPROACHES 
The major component in the medium that affect the growth and myogenic potential of 
satellite cells is the concentration of growth factors. By identifying the contribution of each 
growth factor to the cell propagation, the medium can be optimized. Initially, 23 different growth 
factor concentrations were used in optimizing the medium. Each of these treatments is detailed 
in Appendix D. Briefly, the medium currently used in the Page Lab was used as a control, which 
can be found in Appendix B.  As there are four growth factors present in the medium, the team 
decided to create 23 different combinations of growth factors by removing a single growth factor 
from the medium, removing two growth factors from the medium, and removing three growth 
factors from the medium. In addition, the team also created medium that doubled the 
concentration of a single growth factor or decreased a single growth factor concentration by fifty 
percent. The concentrations for the remaining growth factors remained the same as the control, 
thus only changing one parameter at a time. It is predicted that EGF and FGF2 will have the 
greatest effect on the growth and myogenic potential, therefore when these are removed, a 
significant decrease in the cell population should be noted.  
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After conducting a cell count, BrdU cell proliferation assay, and ICC for myosin heavy 
chain assay, the top ten medium treatments that produced the best results were carried over for 
future testing. A cell count, BrdU, and ICC for myosin heavy chain were completed on these 
treatments again to verify the previous results. The top six treatments that resulted in the most 
positive results were then used for further testing. An ICC for MyoD and myosin heavy chain 
was conducted on these treatments, and then fusion index calculations were conducted to 
determine which treatment yielded the highest myogenic potential. A cost-benefit analysis was 
conducted on any treatment that produced a high myogenic potential in order to select a final 
medium. A visual representation of the process engineering approach can be seen in Figure 10 
below. 
 
FIGURE 10: ENGINEERING PROCESS AND EXPERIMENTAL PLAN TO NARROW DOWN TREATMENT 
MEDIUMS 
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5. PRELIMINARY TESTING AND RESULTS  
Preliminary testing was an important step in determining the direction of this project. This 
chapter outlines results gathered from the approach described in Chapter 4. It also discusses 
these results and explains how they were interpreted. Furthermore, the key conclusions that can 
be made from this data, its impact on decisions, and future testing are discussed. Together, the 
team was able to create correlations between the non-adherent cell population and proliferation 
rate as well as percent differentiation.   
As there were 23 different medium treatments, it would be highly expensive and tedious 
to test each treatment for myogenic potential. Therefore, preliminary testing on each of the 
treatments was conducted. The ratio of adherent to non-adherent cells was calculated to help 
determine the non-adherent contribution to the formation of myotubes. The proliferation of the 
cells was also verified using an ICC for BrdU. Finally, the differentiation of cells was determined 
using an ICC for myosin heavy chain expression. The process and timeline for preliminary 
testing is outlined below. 
5.1 PROCEDURES AND TIMELINE 
After the first passage following the thawing of the human primary satellite cells, 4 mL 
aliquots of the different medium cocktails were created. Using the template found in Appendix 
D, 5,500 cells were plated into each well of a 24-well plate and grown in the different medium 
conditions.  Cells will be plated into three, 24-well plates: one for cell counting, one for the ICC 
for BrdU assay, and one for the ICC for myosin heavy chain. Figure 11 depicts the timeline for 
completing the aforementioned preliminary testing.  
 
FIGURE 11: TIMELINE FOR PRELIMINARY TESTING 
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In order to standardize the results that were obtained, five representative images were 
taken in each well. This was to reflect the overall cell population within each well. As cell growth 
occurred, the central location became very confluent while the outer locations were less. The 
images were taken and data was gathered at the same locations as seen in Figure 12 below.  
 
FIGURE 12: CELL IMAGING LOCATIONS FOR STANDARIZATION OF RESULTS 
5.2 ICC FOR BRDU 
After the cells in the control medium treatment became 40% confluent, the BrdU reagent 
was added to each well and 24 hours later, the assay was conducted. The assay was 
completed within 24 hours because human skeletal muscle satellite cells have a 36-hour full cell 
cycle, and conducting it at his time shows if the treatment medium increases or decreases the 
proliferation rate. This assay works by incorporating the Bromodeoxyuridine nucleotide analog 
into the newly synthesized DNA during the S phase of the cell cycle. The procedure for the 
BrdU testing can be found in Appendix E. After the 24-hour incubation period of the BrdU 
reagent, cells were fixed with methanol-free formaldehyde, and rinsed twice using DPBS with 
divalent cations (Ca++ and Mg++). The nuclei of these cells were then permeabilized using 
0.2% Triton-X-100, and then rinsed with DPBS twice. Cells were then treated with 1.5N HCl, 
rinsed with DPBS, and incubated with anti-Brdu antibody diluted 1:100 in PBS + 0.05% Tween-
20. After incubation, Alexa Fluor 488 was diluted to 1:500 and added to each well. Cells were 
then stained with 0.5μg/mL Hoechst 33342. After washing the stain with DPBS, the cells were 
observed using a Zeiss inverted epi-fluor microscope and imaged using Axiovision software. All 
nuclei fluoresced blue, while the proliferating cells fluoresced green. The ratio of green 
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(proliferated cells) to blue (total cells) indicates the proliferative potential of the cells in the given 
treatment medium. 
Once the cells in the 23 treatments were stained, the percent proliferation for each 
condition was calculated. It was found that nine treatments were significantly higher than the 
control: +50% FGF2, No EGF, -50% IGF, +50% EGF, +50% IGF, Just HGF, -50% HGF, FGF2 
+ HGF, FGF2 + IGF. These nine treatments displayed a proliferation rate that was higher than 
the control. This was required to improve and optimize the current cell culture process by 
producing a higher population of cells.  
5.3 NON-ADHERENT CELL COUNT 
While the cells were being fixed for the BrdU assay, a cell count of adherent and non-
adherent cells was conducted. The supernatant containing the non-adherent cells was 
centrifuged and counted. The adherent cells that remained on the plate were trypsinized, 
centrifuged, and counted. Using this quantitative data, the ratio of non-adherent cells to total 
cells was established.  
After the cell count of the adherent and non-adherent cell populations were conducted, 
the team analyzed the total cell count as well as percent of non-adherent cells for all 23 
treatments. It was found that three treatments had a total cell count around or higher than the 
control: +50% FGF2, -50% EGF, and +50 EGF. Further, seven treatments had a non-adherent 
population of higher than 35%: +50% FGF2, No EGF, -50% EGF, +50% EGF, No IGF, -50% 
IGF, -50% HGF. Note that the three treatments that had a high cell count also had a high non-
adherent population. The data for all 23 treatments is not shown, however, the highlights of this 
data just described can be found in Table 4, below.  
TABLE 4: PRELIMINARY CELL COUNT HIGHLIGHTS 
 All GFs 
(Control) 
+50% 
FGF2 No EGF 
-50% 
EGF 
+50% 
EGF No IGF 
-50% 
IGF 
-50% 
HGF 
Total Cell 
Count 49000 47000 28750 43500 52750 15000 14500 20750 
Percent 
Non-
Adherent 
34.7% 38.4% 40.2% 41.2% 36.5% 35.3% 35.7% 35.9% 
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5.4 ICC FOR MYOSIN HEAVY CHAIN 
Simultaneously, as the cell count was completed, differentiation medium was added to 
the plate intended for ICC for myosin heavy chain testing. After 1 week of differentiation, this 
assay was completed. This procedure is explained in detail in Appendix E. Cells were fixed in 
methanol-free formaldehyde, permeabilized using 0.2% Triton-X-100, and rinsed using DPBS 
with divalent cations. Blocking solution (3% FBS) was added to each well at 150 µL per well, 
and incubated. The primary antibody MF20 (Developmental Studies Hybridoma Bank), diluted 
at 1:500 in DPBS/0.05% Tween-20, was added, incubated for 30 minutes, aspirated, and rinsed 
with DPBS three times, for three minutes per wash. Following the aspiration of the DPBS, Alexa 
Fluor 488 conjugated secondary antibody (Invitrogen) diluted at 1:500 in DPBS/0.05% Tween-
20 was added to each well and then the plate was incubated for 30 minutes. After the incubation 
period, each well was rinsed three times with DPBS, stained with 0.5µg/mL Hoechst 33342, and 
rinsed and stored in DPBS. Each well was then observed using a Zeiss inverted epi-fluor 
microscope and imaged using Axiovision software. The cell nuclei were stained blue, while the 
differentiated cells that expressed myosin fluoresced green. From this data, the differentiation 
percentage was determined.  
Finally, once the ICC for myosin heavy chain data was collected, the percent of 
differentiated cells were calculated. From analyzing the results it was found that five treatments 
had higher than 20% differentiation: +50% FGF2, Just FGF2, Just IGF, FGF2 + IGF, -50% HGF. 
By having a high differentiation into myotubes, the number of cells that can be used in a clinical 
setting is increased. It is necessary for this percentage to be optimized to ensure that the 
maximum number of cells is carried through differentiation and into clinical applications.  
5.5 PRELIMINARY DATA CONCLUSIONS 
After comparing the results from all three tests, the teamed selected the top ten 
treatments that exhibited a combination of an increased proliferation, differentiation, or non-
adherent cell population. A correlation was established between the percent of non-adherent 
cells and these results. Although some treatments showed a high proliferation rate over a 24-
hour period, after three days they did not exhibit the highest cell counts or non-adherent 
population. Therefore, +50% IGF, Just HGF, and FGF2 + HGF were eliminated from further 
testing. Similarly, -50% IGF was removed from further testing because it exhibited a low 
differentiation percentage. FGF2 + IGF was also rejected because it displayed a very low non-
adherent cell population which is important for myogenic potential. The top ten treatments 
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selected for further testing and validation were: Control, +50% FGF2, No FGF2, +50% EGF, No 
IGF, Just FGF2, -50% FGF2, No EGF, -50% EGF, -50% HGF.   
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6. PRELIMINARY DATA VERIFICATION 
This chapter discusses the verification process in the growth of the human primary satellite 
skeletal muscle cells. The cell culturing procedure used in the Page Lab is tested and verified 
through analyzing the results described in each of the sub-sections below. Through the 
confirmation of these results, the team can further develop the optimization of cell proliferation 
and differentiation. 
 
6.1. CULTURING OF HUMAN PRIMARY SATELLITE CELLS 
The verified process for culturing human primary satellite cells is divided into more detailed 
descriptions in the sections below. These sub-sections include an overview of this cell line, the 
medium combination process, how to thaw cells, and specifics related to the culture of adherent 
and non-adherent cells.  
 
6.1.1. HUMAN PRIMARY SATELLITE CELLS 
The cells used in this project were derived from a human skeletal muscle primary 
satellite cell line. This cell line was chosen because they are a cell type that can be used for 
autologous cell therapy. The cells were obtained from a Worcester Polytechnic Institute frozen 
stock, and were cultured in an incubator at 37oC with 5% CO2.  
 
6.1.2. MAKING MEDIUM 
Cells need to be exposed to a healthy, nutrient-rich environment in order to remain 
viable. In this project, proliferation medium of 54% Dulbecco’s Modified Eagles Media (DMEM), 
36% F12, 10% FCIII, 4 mM glutamine, and 1X penicillin/streptomycin was used as a base 
medium. Growth factors (EGF, FGF2, HGF, and IGF) were also incorporated into the 
proliferation medium. These concentrations varied based on the medium treatment that was 
used. Differentiation of the primary cells was induced by replacing the proliferation medium with 
differentiation medium. This medium contained 58.2% DMEM, 38.8% F12, 2% Horse serum, 
1% ITS, 4 mM Glutamine, and 1X penicillin/streptomycin.   
Initially, antibiotics were not used in the testing of these cells; however various bacterial 
contamination issues occurred during the beginning phases of testing. While sterile techniques 
were used throughout the culturing process, there was an increased risk of contamination due 
to the shared workspace within the laboratory. As a result, a small amount of antibiotics were 
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used in an attempt to reduce this risk. After the incorporation of these antibiotics, no more 
contamination issues were observed.  
 
6.1.3. THAWING CELLS 
To preserve cellular function and viability, large cell harvests are generally frozen 
through the process of cryopreservation. In order to use the cells at later time, they need to be 
thawed through a sensitive process. To restart the cell line, one must quickly thaw the vial to 
avoid high levels of toxicity in the cells as a result of the dimethyl sulfoxide (DMSO) they were 
suspended in during the freezing process. The vial must be diluted with medium almost 
immediately, to diminish the effects of the DMSO. The cryopreservation and thawing processes 
can be found in Appendix C.   
 
6.1.4. SUBCULTURING ADHERENT AND NON-ADHERENT CELLS 
It is commonly thought that cells that are non-adherent, in a cell population that is known 
to be adherent, are dead. However, some preliminary observations have shown that both of 
these cell populations exist as healthy cells, when culturing human primary satellite skeletal 
muscle cells. When observing these cells in culture, doublings can be seen indicating that these 
non-adherent cells are still alive. When subculturing these cells, the non-adherent cell 
population is not discarded; rather, both adherent and non-adherent are passaged into a new 
culture together.  
 
6.2. ICC FOR BRDU 
Following the same procedure described in section 5.1, cells were stained to detect the 
nuclei as well as proliferating cells. The ratio of proliferated cells to total cells counted indicates 
the proliferated potential of the cells in the given treatment medium. Cells were allowed to 
proliferate for forty-eight hours in treatment medium. BrdU labeling reagent was then added, 
and after 24 hours cells were fixed and stained. Figure 13, below, displays the proliferative cells 
for the ten treatment mediums.  
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FIGURE 13: PERCENT BRDU POSITIVE CELLS AFTER 24 HOURS OF TOP TEN TREATMENTS 
From Figure 13, above, it can be observed that four treatment mediums that were 
distinctively above 30% proliferation. These treatments include the control of All GFs, +50% 
FGF2, No EGF and No IGF. These treatments show potential to maintain a high proliferative 
state while maintaining the potential for a high cell count or percent differentiation. 
Representative images of these four treatment mediums can be seen below in Figure 14. Note 
that the total cell population is colored blue while the BrdU positive cells are depicted in red.  
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FIGURE 14: BRDU POSITIVE CELL (RED), TOTAL CELLS (BLUE) A) ALL GFS (CONTROL), B) +50% 
FGF2, C) NO EGF AND D) NO IGF  
As seen from Figure 14, +50% FGF2 and No IGF show a substantially higher 
proliferation rate than the control of All GFs.  
6.3. NON-ADHERENT CELL COUNT 
As the BrdU assay was completed, a cell count of the adherent and non-adherent 
populations was conducted. The total cell population was calculated by adding the adherent and 
non-adherent cell populations. Table 5, below, displays these results.  
TABLE 5: TOTAL AND PERCENT NON-ADHERENT CELL COUNTS OF TOP TEN TREATMENTS 
 All GFs (Control) 
Just 
FGF2 
No 
FGF2 
-50% 
FGF2 
+50% 
FGF2 No EGF 
-50% 
EGF 
+50% 
EGF 
-50% 
HGF No IGF 
Total 
Cell 
Count 
78333 
± 2887 
48333 
± 10408 
53333 
± 11547 
68333 
± 2887 
71667 
± 20207 
73333 
± 2887 
65000 
± 5000 
53333 
± 7638 
36667 
± 2887 
43333 
± 14434 
Percent 
Non-
Adherent 
23.4% 
± 7.7 
21.7% 
± 8.1 
17.5% 
± 8.8 
24.6% 
± 18.0 
35.5% 
± 7.8 
32.7% 
± 9.6 
28.8% 
± 9.6 
36.2% 
± 9.8 
29.8% 
± 13.1 
26.8% 
± 13.8 
 
From the table above, it can be observed that three treatment mediums produced a cell 
count above 70,000 cells after 72 hours of proliferation: All GFs, +50% FGF2 and No EGF. It 
can also be seen that +50% FGF2 and No EGF created a higher percent non-adherent 
A B
 
C D
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population of 35.5% and 32.7% respectively. This is approximately 10% higher than the control 
of All GFs. The two treatment mediums of +50% FGF2 and No EGF, which produced the high 
total population as well as the high percent of non-adherent population, can be seen in Figure 
15 compared to the Control.  
 
FIGURE 15: BRIGHT FIELD IMAGES OF TOTAL CELL POPULATIONS, A) ALL GFS (CONTROL) 
B)+50% FGF2, AND C) NO EGF 
  As seen from Figure 15, above, the +50% FGF2 and No EGF treatment mediums have a 
noticeably higher non-adherent cell population, as observed by the phase bright cells.  
6.4. ICC FOR MYOSIN HEAVY CHAIN 
When the ICC for BrdU assay and cell counts were conducted, cells were also placed into 
differentiation medium for 10 days. The procedure used was identical to that observed in 
Section 5.4. The blue stain indicated the cell nuclei, and green indicated the myosin heavy chain 
protein, which is expressed after differentiation. The data can be seen in Figure 16, below.  
A B C 
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FIGURE 16: ICC FOR MYOSIN HEAVY CHAIN, AFTER TEN DAYS OF DIFFERENTIATION, FOR TOP 
TEN TREATMENTS 
 The data presented in Figure 16 shows three growth factor treatments that 
demonstrated a percent differentiation above 30%: All GFs, Just FGF2, +50% FGF2. However, 
it was noted that a high differentiation percentage does not indicate a high myogenic potential 
because some cells that differentiated were only a single cell and did not form multinucleated 
myotubes. Representative images of All GFs, Just FGF2 and +50% FGF2 can be seen in 
Figure 17, below. The total cell population was stained blue while the differentiated myosin 
positive cells were stained green.  
 
FIGURE 17: MYOSIN HEAVY CHAIN (GREEN), CELL NUCLEI (BLUE), A) CONTROL, B) JUST FGF2, 
C)+50% FGF2 
As seen in Figure 17, above, Just FGF2 has a considerably higher percent differentiated 
cells when compared to the control where +50% FGF2 has a slight increase in differentiation.  
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6.5. PRELIMINARY DATA VERIFICATION DISCUSSION 
Through analyzing the data in 6.2, 6.3 and 6.4, it was found that six treatment mediums 
showed potential to have a high myogenic potential by having a high proliferation, cell count, 
percent non-adherent population and percent differentiation. In addition to the control, +50% 
FGF2, No EGF and No IGF demonstrated a high proliferation rate, which was an important 
criteria to meet as the team determined that the cells must grow around the same rate as the 
currently used medium. Further, +50% FGF2 and No EGF also demonstrated a high cell count 
as well as a high percent non-adherent population. Since it is speculated that the non-adherent 
population may correlate to a high myogenic potential, these two treatments are especially of 
interest. Lastly, from the ICC for myosin heavy chain, it was found that Just FGF2 produced a 
high-differentiated population after ten days. In addition to these highlighted treatments, -50% 
HGF was also considered as overall it was slightly below the proliferation and had a higher 
percent non-adherent population compared to the All GFs treatment (control). Therefore, the top 
six treatments that were selected for further examination were the control of All GFs, Just FGF2, 
+50% FGF2, No EGF, -50% HGF and No IGF.  
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7. FINAL DESIGN AND RESULTS 
This chapter discusses the myogenic potential and MyoD expression of the cells in the 
top six treatment mediums. From this data, the team can further determine if there is a 
correlation between MyoD expression and myogenic potential, as well as the effect of the non-
adherent cell population on the consistency of myogenic potential throughout differentiation.  
7.1. IMMUNOCYTOCHEMISTRY FOR MYOGENIC POTENTIAL 
To confirm the myogenic potential of the differentiated muscle cells, an ICC assay for 
myogenic potential was conducted. Cells were grown in the treatment mediums until a 
confluence of 80% was reached. At this point, the differentiation medium was added, and 
differentiation was induced for 10 days before testing. To begin the ICC assay, mirror cultured 
cells were stained for MyoD with 5.2 MyoD Clonal Antibody (AbCAM) or MF20 antibody for 
myosin heavy chain (DSHB). Secondary antibodies Alexa Fluor 568 and Alexa Fluor 488 were 
used to make the MyoD and myosin heavy chain fluoresce red and green respectively. These 
two tests were run at four time points post differentiation: t=0, 3, 5, & 10 days. Wells were 
imaged using Leica DMIL LED microscope and IC Capture 2.1 software. 
7.1.2 ICC FOR MYOD 
MyoD expression was examined over these time points. If cells do not display MyoD, 
they will be considered to be going through the later stage of differentiation since MyoD is 
typically up regulated in the cell when differentiation is induced (De Angelis et. al., 1999; 
Portmann-Lanz, 2006). This test was also used to determine if MyoD could be used as an early 
marker for myogenic potential by comparing the MyoD expression results to the fusion index 
results seen in section 7.1.3.  Results for MyoD expression over the four time points can be 
seen below in Figure 18.  
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FIGURE 18: RESULTS OF MYOD EXPRESSION OVER 10 DAY PERIOD FOR THE TOP SIX 
TREATMENTS 
As seen in the graph above, MyoD expression was relatively constant for all treatment 
mediums except for +50% FGF2. It is seen that MyoD is expressed at a high rate very early on 
in differentiation. Images for the All GFs, +50% FGF2, and No EGF treatment mediums at Day 5 
can be observed in Figure 19. MyoD positive cells were stained red while the total cell nuclei 
were stained blue.  
 
FIGURE 19: MYOD EXPRESSION AT DAY 5, MYOD (RED) AND TOTAL CELLS (BLUE), A) ALL GFS 
(CONTROL), AND B) +50% FGF2, C) NO EGF.  
Note: Images are not as fluorescently bright as observed. This is because the imaging system 
used was switched over to a different camera prior to imaging this data set.  
As seen in Figure 19, above, the +50% FGF2 treatment medium had a higher 
expression of MyoD, compared to the control, at an early stage in differentiation. From Figure 
18, it can be seen that the overall trend of all treatment mediums is cells that are in a later stage 
A B C 
A B C 
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of differentiation, MyoD expression decreases, as expected. This data will be compared with the 
calculated fusion index to determine if there is a correlation so MyoD could be used as an early 
marker for myogenic potential.  
7.1.3 FUSION INDEX & MYOGENIC POTENTIAL 
Myogenic potential is an important characteristic of muscle cell differentiation. It can be 
described as the likelihood of the differentiated cells to form multinucleated myotubes and 
ultimately functioning muscle. To test for myogenic potential an ICC for myosin heavy chain was 
completed and a calculation was conducted. The same process aforementioned in section 6.4 
was followed to complete this ICC for myosin heavy chain, staining for the myosin heavy chain 
with Alexa Fluor 488 (green) and nuclei with Hoechst (blue). The full protocol can be found in 
Appendix E. 
Myogenic potential can be calculated using a mathematical equation called the fusion 
index. The Fusion Index, in Equation 1 below, is equal to the number of nuclei present in a 
myotube divided by the total nuclei present in the culture (Yang et al., 2010). 
EQUATION 1: FUSION INDEX FORMULA 
𝐹𝑢𝑠𝑖𝑜𝑛 𝐼𝑛𝑑𝑒𝑥 =  𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑢𝑐𝑒𝑙𝑖 𝑖𝑛𝑠𝑖𝑑𝑒 𝑚𝑦𝑜𝑡𝑢𝑏𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑐𝑒𝑙𝑖  
An example of this calculation can be seen using the Figure 20 below as a sample group. The 
green in this image represents the differentiated cells and the nuclei are seen in blue. 
 
FIGURE 20: DIFFERENTIATED CELLS CONTAINING MULTINUCLEATED MYOTUBE FORMATION. 
For example, from the image above, it can be determined that there are five nuclei 
present in myotubes, while 13 nuclei are contained in any differentiated cell. The total nuclei 
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present in Figure 20 were 35. This image displays a 14.3% myogenic potential in this cell 
population.  
A calculation for fusion index was performed on each of the top six treatments to 
determine the myogenic potential over a 10-day period focusing on time points 0, 3, 5, and 10. 
This data is displayed in Figure 21, below. 
 
FIGURE 21: THE MYOGENIC POTENTIAL TRENDS OVER A 10 DAY TIME PERIOD POST 
DIFFERENTIATION OF THE TOP 6 TREATMENTS. 
Figure 21, above, shows all six treatments, which follow a similar trend based on the 
myogenic potential calculated at all four time points. The +50% FGF2 and No EGF treatments 
display the highest myogenic potential over a 10-day time period. These two treatments also 
showed the most consistent myogenic potential throughout these ten days. It is important to 
note that these two treatments also showed the highest non-adherent cell populations.  This 
supports the previously stated hypothesis that an increased non-adherent population increases 
the myogenic potential.  
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8. CONCLUSIONS AND RECOMMENDATIONS 
8.1. COST-BENEFIT 
Before a final medium was chosen, the team had to research the cost it would take to 
scale up for clinical applications. First, the amount of medium required to grow the amount of 
cells needed to treat a 15 cubic cm wound was determined. This was estimated to be around 30 
billion cells. Next, the final cost to grow these cells in the prescribed medium amount was 
calculated. A starting cell population of 500,000 cells was used. It was assumed that cells would 
propagate with a 36-hour doubling time, and would be passaged into T-75 flasks every 72 
hours. The final costs for the control and the top two treatment mediums that exhibited the 
highest myogenic potential are shown in Table 6 below.  
TABLE 6: COST ANALYSIS OF CONTROL AND TOP TWO TREATMENT MEDIUMS 
Component 
Commercial Price Control +50% FGF2 No EGF 
Amount Price 873.81 L of Medium 873.81 L of Medium 873.81 L of Medium 
DMEM 6 X 500 mL  $115.46   $16,777.15   $16,777.15   $16,777.15  
F12 6 X 500 mL  $98.67   $10,310.96   $10,310.96   $10,310.96  
FCIII 12X 500 mL  $153.42   $2,271.91   $2,271.91   $2,271.91  
Glutamine 100 g  $87.92   $524.29   $524.29   $524.29  
Growth Factors      
FGF2 (4ng/mL) 10 ug solid  $80.00   $27,961.92   $41,942.88   $27,961.92  
HGF (2.5ng/mL) 10 ug solid  $195.00   $42,641.93   $42,641.93   $42,641.93  
IGF (5.0ng/ml) 50 ug solid  $195.00   $17,126.68   $17,126.68   $17,126.68  
EGF (2.5ng/ml) 500 ug solid  $195.00   $873.81   $873.81   
 Total Cost:  $118,488.64   $132,469.60   $117,614.83  
  
As shown in the table, +50% FGF2 adds an addition $13,980.96 to the total production 
cost while No EGF reduces the cost by $873.81 when compared to the control medium. After 
the cost was determined, the team looked into the overall results from all of the assays 
completed as seen in Table 7.  
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TABLE 7: COST-BENEFIT ANALYSIS OF CONTROL AND TOP TWO TREATMENT MEDIUMS 
 Control +50% FGF2 No EGF 
Proliferation (%) 34.4 ± 13.4 37.6 ± 15.0 31.8 ± 14.4 
Differentiation (%) 34.3 ± 19.3 36.6 ± 26.0 14.3 ± 4.0 
Percent non-adherent 
(%) 23.3 ± 7.7 35.5 ± 18.0 32.7 ± 9.6 
Myogenic Potential (%)  
(t=10 days) 27.1 ± 2.2 41.0 ± 5.9 47.3 ± 6.5 
Cost to treat a 15 cm3 
wound $118,488.64 $132,469.60 $117,614.83 
 
 As seen in the Table 7, the two treatment mediums have the same proliferation rate as 
the medium currently used, however both treatments yielded a higher non-adherent cell 
population. The two treatments with a higher non-adherent population also displayed a 
drastically higher myogenic potential than the control. This supports the theory that the non-
adherent population correlates to a higher myogenic potential. One thing to note is the 
differentiation of the No EGF treatment medium. While this is low, it did form the most 
multinucleated myotubes. Differentiation in other treatment mediums may have had a higher 
differentiation percentage, however these cells were mononucleated. In addition, No EGF had a 
consistently lower standard deviation, which suggests that it provides a more reliable and 
repeatable process.  
8.2. OVERALL CONCLUSIONS 
Based on results, and the cost-benefit analysis, the team determined the No EGF 
treatment medium was the best option for the growth and differentiation into multinucleated 
myotubes. This medium maintains the same proliferation rate; however, it produces nearly a 
twofold increase in myogenic potential. One of the goals of this project was to optimize the 
myogenic potential of the culture to greater than 30%, which is met with the No EGF treatment. 
In addition, it reduces the cost needed to expand the cells for autologous cell therapy 
applications.  
In addition, it was found that whenever the percent non-adherent cells increased in a 
treatment medium, the myogenic potential of those cells also increased.  Therefore, these cells 
should not be discarded when culturing. This can be seen through the analysis of the gathered 
results. The treatment Just FGF2 had a low percent of non-adherent cells, whereas the No EGF 
treatment had one of the highest percent of non-adherent cells. In comparing their results in the 
final myogenic potential graph, you can see that although the Just FGF2 started with the highest 
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myogenic potential at day three, it’s myogenic potential dropped drastically as time progressed. 
The No EGF treatment had a fairly high myogenic potential at day three, but it remained fairly 
constant with increasing time. This data supports the theory that the increased non-adherent 
cell population provides a higher myogenic potential over time.  
Lastly, it was found that when cells are cultured in +50% FGF2, that MyoD was 
expressed early in differentiation. A correlation was made between cells grown within this 
treatment medium as they also exhibited a high myogenic potential. When clinical therapies are 
being conducting, a biopsy from the patient would be obtained. Those cells would then grow in 
our recommended No EGF treatment medium. To ensure that the population will still have a 
high myogenic potential, a small subculture would then be started in +50% FGF2 treatment 
medium. MyoD expression can then be examined to ensure that the cell culture will have a high 
myogenic potential since +50% FGF2 and No EGF have relatively the same myogenic potential. 
8.3. FUTURE RECOMMENDATIONS  
    Further tests should be conducted with the final proposed medium to ensure the 
functionality and long-term effects of the cells in this medium.  
 
• Single cell contraction assay: It is important to ensure that the medium chosen does 
not inhibit the cellular function. The myotube function can be tested through a single cell 
contraction assay. This bench top assay has not previously been tested on human 
primary satellite cells, but has been used successfully for cilliary muscle cells. The 
researchers state that it can be used for any slow growing, calcium induced contraction 
cells. After cells have differentiated they should be treated with a calcium free non-
enzymatic dissociation buffer, followed by atropine and carbachol. The dissociation 
buffer removes the cells from the plate without disrupting their membranes. The atropine 
will allow the cell to shrink in size while the carbachol causes it to expand. These two 
chemicals together induce an environment in which the cells can be seen contracting. A 
way of measuring the contractile ability of these cells should be determined in order to 
compare the chosen treatment to the control medium. This protocol can be found in 
Appendix E.  
• Long-term medium effects: While this medium did exhibit a high myogenic potential, 
the longevity of this characteristic is unknown. In addition, the medium could extend the 
Hayflick Limit of this cell line. Therefore, long-term cell cultures should be conducted to 
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determine if any long-term effects are present, highlighting any positive or negative 
contributions.  
• Altering culture surfaces and ambient oxygen: Cell culture environment has a 
significant contribution to cellular growth. It is possible that by altering the cell culture 
surface the adherent population will become smaller as it may not adhere. This could 
lead to a higher non-adherent population, and thus potentially a higher myogenic 
potential. Further studies researching the effects of oxygen levels should also be 
conducted. Lower oxygen levels mimic the in vivo environment; therefore by having a 
culture system that represents the in vivo environment more, cells may respond 
differently to treatment mediums. 
• Alternative designs: While the team decided to optimize the medium to meet the needs 
presented by the client, the three other alternative designs proposed in Chapter 4 should 
be extensively looked into. This could make the process of culturing these cells easier by 
eliminating some extent of human contact when passaging, and therefore reducing the 
risk of losing cells.  
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APPENDIX  
APPENDIX A: GANTT CHART 
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APPENDIX B: MEDIA RECIPES 
Note: All media should be warmed prior to adding to cells. Cold media, from the refrigerator may kill 
your cells.  
 
Human Primary Cell Proliferation Media  
Component Volume for 50 mL Final Concentration 
60% DMEM 25 mL 54% 
40% F12 18 mL 36% 
FCIII 5 mL 10% 
FGF2 20 μL n/a 
IGF 5 μL n/a 
EGF 2.5 μL n/a 
HGF 12.5 μL  n/a 
4mM Glutamine 0.02922 g  n/a 
Final Volume 50 mL  100% 
 
Human Primary Cell Differentiation Media  
Component Volume for 50 mL Final Concentation 
60% DMEM 29.1 mL 58.2 % 
40% F12 19.4 mL 38.8% 
Horse Serum  1 mL 2% 
ITS 0.5 mL 1% 
4mM Glutamine 0.02922 g n/a 
Final Volume 50 mL 100% 
 
 
C2C12 Proliferation Media (“Cell Culture Manual-Detailed”, 2010) 
Component Volume for 50 mL Final Concentration 
Penn Strep 0.5 mL 1% 
Glutamax 0.5 mL 1% 
FBS 5 mL 10% 
50%/50% DMEM/F12 44 mL 88% 
Final Volume  50 mL 100% 
 
 
C2C12 Differentiation Media (“C2C12 Differentiation”, 2012) 
Component Volume for 10 mL Final Concentration 
Horse Serum 200 μL 2% 
ITS 100 μL 1% 
Glutamax 100 μL 1X (2mM) 
Penn Strep 100 μL 1X (1%) 
50%/50% DMEM/F12 9.5 mL 95% 
Final Volume  10 mL 100% 
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Freezing Media (“Cell Culture Manual-Detailed”, 2010) 
Component Volume for 10 mL Final Concentration 
DMSO 2 mL 20% 
FBS 1 mL 10% 
DMEM 7 mL 70% 
Total Volume 10 mL 100% 
 
1. Determine the total volume of media needed, then calculate the volume of each component 
which needs to be added to reach this total volume of media.  
2. Pipet the required amount of media and componenets into a 50mL, 150mL, or 500 mL filter 
unit.  
3. Filter sterilize the media into a clean, sterile container. Cap the containers and leave in the 
hood until you are finished.  
4. Attach vacuum line to the Steriflip side-arm, turn on vacuum and continue pulling until all 
media has mostly filtered through. Turn off pump. Remove vacuum line when all media has 
been pulled into the lower tube (ignore bubbles).  
5. Remove Steriflip filter and top tube then discard in biohazard trash. Cap the bottom (media 
containing) tube with the sterile cap provided in the Steriflip package.  
 
(“Making Media”, B 2011) 
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APPENDIX C: CULTURE PROTOCOLS 
THAWING CELLS  
1. Place an empty 15mL conical tube in the hood, and then obtain a cryotube of the desired 
cells. Place the cryotube in the 37° C water bath to thaw quickly. While thawing label the 
conical tube with your initials, and transfer your warmed media to the hood along with other 
necessary supplies. Cells must not be left in the water bath any longer than needed for 
thawing (1-2 min). 
2. When thawed, rinse the outside of the vial with ethanol and wipe dry, then place the tube in 
a rack in the hood. Make sure all ethanol has evaporated before opening the tube as ethanol 
is toxic to the cells! 
3. Using a 1 mL pipet gently re-suspend the contents of your cryovial by pipetting up and down, 
without creating bubbles, then gently transfer entire suspension to the 15 mL conical tube. 
Very slowly add 10 mL of warm medium down the inside to the tube: one drop, then 2-3, 
then 4-6 drops, etc. with gentle hand mixing (tap tube on side) between each addition, for at 
least the first 5 mL. It should take 2-3 minutes to add all of the media. 
4. Cap tightly, gently mix the cell suspension by slowly inverting the tube 2-3 times, then 
centrifuge for 5 minutes at around 1200 rmp. Re-wipe the tube with 70% EtOH (taking care 
not to disturb the cell pellet) and return to the hood. 
5. Aseptically attach a sterile, glass, Pasteur pipet to the end of the vacuum line. Turn on the 
pump, uncap the tube and aspirate off as much medium as possible without disturbing the 
pellet.  
6. Re-suspend the pellet in 2 mL of medium. Perform a cell and viability count. Determine the 
total live cells/mL, which will be used in the next step. If the cell number is already known 
proceed to step 8 and do not perform a cell and viability count. 
7. Determine the volume of cell suspension (‘V’) that contains the appropriate # of live cells for 
the experiment. For subculturing, 200,000 cells are needed for a T75 flask. 
8. Plate your cells in a T75 flask with a final total volume of 10 mL: 
a. Place a T75 flask in the hood and add 10 - V mL (‘V’ from step 7) of media down the 
back of the flask. This is the large surface that will be on the bottom, when you set 
the flask down so that the canted neck is pointing upward; example: If you will be 
adding 0.5 mL of cells, you must put 10.0 - 0.5 = 9.5 mL in the flask. Note: if V is less 
than 0.1 mL use a full 10 mL of media. 
b. Gently re-suspend the cells, then remove (use an appropriate size pipet) the required 
volume of cell suspension determined in step 7 and place it in the T75 flask by gently 
dispensing the liquid down the back of the flask. If you do not have enough cell 
suspension, add all that you have. 
c. Cap the flask tightly (vented flasks only), mix and distribute the cell/media mixture by 
gently rocking the flask to coat the entire bottom with cell suspension (hold 
horizontally, with the canted neck slanting up). When finished, place the flask in the 
incubator. Aspirate any excess cell suspension, then clean the vacuum line by rinsing 
with 70% EtOH, and discard cryovial in biohazard can. 
 
(“Thawing Cells”, B 2011)  
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TRYPSINIZING, COUNTING AND PASSAGING ADHERENT CELLS 
1. Take flasks out of incubator  
2. Remove media with a serological pipette and place in a 15mL conical tube (These are the 
non-adherent cells!!)  
3. Label tube for non-adherent cells (N) and fill with media (without growth factors).  
4. Place aside until the adherent cells are in a conical tube as well. If adherent cells are not 
being typsonized, skip to step 7. 
5. Once the non-adherent cells are removed, add 1 mL of 0.05% trypsin, hold horizontally (cell 
layer down) and gently rock the flask to cover the entire layer of cells with trypsin. Let sit for 
30 seconds, gently rock flask, and then start looking at the cells by eye. Alternate gently 
rocking and observing until all of the monolayer has released and most of it has broken into 
small piece. As soon as most of the monolayer completely breaks apart proceed to the next 
step. (Note: it will be noticeable around the edges when the cells are coming off the plate) 
6. Once most the cells are off the plate, add 5 mL of proliferation media (without growth 
factors) and vigorously wash the bottom surface of the flask, pipetting up and down. Squirt 
the suspension several times against the bottom of the flask, to break up all cell clumps. 
When you have a uniform suspension transfer it to a 15 mL conical tube and label it for 
adherent cells (A).  
7. Spin down conical tubes for 5 minutes at 2.5-3 speed.  
8. Aspirate off the medium, re-suspend the cell pellet in 5 mL of proliferation media (with 
growth factors). Again, pipet up and down until no clumps is visible. This is extremely 
important so that the cells are properly mixed. (Note: The pellet may be small and on the 
side of the tube).  
9. Remove a 100 μL aliquot and place in an eppendorf tube. In the same tube add 100 μL 
aliquot of trypan blue. Close the tube and mix thoroughly by flicking and inverting.  
10. Count cells in each of the four large corners in a hemocytomer by adding 10 μL of cell-trypan 
mixture to each side. Dead cells will appear blue while alive cells will appear normal.  
11. Take an average of the four corners to obtain average cell count.  
12. Multiply this value by 10,000 (volume of grid). Multiply again by 2 (dilution factor). And 
multiply again by how many mLs you suspended in. This value will be your total cell count.  
13. Use the following formula to determine how many mls of cell suspension and media should 
go in the flask: 
V of cell suspension needed = (number of cells needed)/(number of total cells) 
V of media (with GF) needed = 5 mL (for T25) – (V of cell suspension needed) 
14. Place the calculated amount of cells in a new T25 or T75 flask and then add the proper 
amount of media. Note: If a T25 flask is used the final volume should be 5mL while if a T75 
flask is used the final volume should be 10mL. 
15. Label flask with today's date, your initials, the cell line and media, then place in the 
incubator. 
16. Aspirate any leftover culture. Discard the aspirator pipet and clean the aspirator line with 
70% EtOH. Open aspirator line and turn off pump. 
 (“Trypsonizing and Plating of Adherent Cells”, B 2011) 
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CELL DIFFERENTIATION 
 
Human Primary Cell Differentiation Media 
Component Volume for 50 mL Final Concentation 
60% DMEM 29.1 mL 58.2 % 
40% F12 19.4 mL 38.8% 
Horse Serum  1 mL 2% 
ITS 0.5 mL 1% 
4mM Glutamine 0.02922 g  
Final Volume 50 mL  
 
 
Procedure 
1. Grow cells in proliferative media in 24-well plates at the desired cell density.   
2. On the day of start of differentiation (D0), aspirate complete medium from wells.  
3. Rinse once with 1X DPBS.  
4. Add 500 µl differentiation medium per well. 
5. Continue culturing cells until they differentiate and form myofibrils (usually 7 to 10 days). 
6. Periodically check the wells for proliferation and change media if necessary. The cells 
may continue to proliferate for the first 3-5 days until they slow down and exit 
proliferation and start to differentiate. 
7. Successful differentiation results in about 30 to 50% of the cells aligning and fusing to 
form multinucleated myofibrils.  
 
BrdU labeling of cells to determine cell proliferation or lack thereof: 
If you plan to determine the time point at which cells exit proliferation and start differentiating, 
follow the protocol below. 
 
1. Add 50 ul of BrdU labeling reagent (Invitrogen, Cat # 00-0103) to 500 ul medium (about 
1:10 final dilution) in 24-well plates. 
2. Continue culturing cells for the required amount of time (2 hours to overnight incubation). 
3. Fix the cells and save in DPBS at 4o C until further analysis. 
4. Follow BrdU or ICC protocol to determine stage at which cells exit proliferation.  
 
(C2C12 Differentiation, 2012) 
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APPENDIX D: TESTING REGIMENS 
 Below is the template used when plating the cells onto the 24-well plates for preliminary 
testing. As there was an ICC for BrdU assay, cell counting assessment, and ICC for myosin 
heavy chain completed on each of the medium conditions, the plates were seeded in triplicate, 
so one plate was devoted to one specific assay.   
PLATE A 1 2 3 4 5 6 
A CONTROL CONTROL Just FGF2 Just EGF Just IGF Just HGF 
B EGF + FGF2 FGF2 + IGF No FGF2 No EGF No IGF No HGF 
C EGF + IGF FGF2 + HGF -50% FGF2 -50% EGF -50% IGF -50% HGF 
D EGF + HGF IGF + HGF +50% FGF2 +50% EGF +50% IGF +50% HGF 
 
The well map below is the 10 treatments that an ICC for BrdU and ICC for myosin heavy 
chain were conducted on for verification of the first 23 treatment results. Since each of these 
treatments were completed in duplicate, only one plate was seeded with cells. Data obtained 
from this plate was compared with the results from the initial preliminary testing.  
PLATE A 1 2 3 4 5 6 
A CONTROL +50% FGF2 -50% FGF2 +50% EGF -50% HGF   
B CONTROL +50% FGF2 -50% FGF2 +50% EGF -50% HGF   
C Just FGF2 No FGF2 No EGF -50% EGF No IGF   
D Just FGF2 No FGF2 No EGF -50% EGF No IGF   
 
The following well map shows the 6 most promising treatments for cellular growth and 
myogenic potential. An ICC for MyoD was conducted on rows A and B, while an ICC for myosin 
heavy chain was completed on rows C and D. As this test was completed at four different time 
points (0, 3, 5, and 10 days), the four plates were seeded. Using the myosin heavy chain data, a 
fusion index was calculated.  
PLATE A 1 2 3 4 5 6 
A CONTROL Just FGF2 +50% FGF2 No EGF -50% HGF No IGF 
B CONTROL Just FGF2 +50% FGF2 No EGF -50% HGF No IGF 
C CONTROL Just FGF2 +50% FGF2 No EGF -50% HGF No IGF 
D CONTROL Just FGF2 +50% FGF2 No EGF -50% HGF No IGF 
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APPENDIX E: ASSAY PROTOCOLS 
ICC FOR BRDU ASSAY 
Procedure 
1. Add 1.0 μl of BrdU stock solution per ml of culture medium to cells being assayed and 
incubate for 24 hours or the time required by the experimental protocol. 
2. Aspirate culture medium and wash cells in 2X in DPBS+. 
3. Add 500 µL of methanol-free formaldehyde into each well. Incubate at room temperature 
for 10 minutes.  
4. Aspirate formaldehyde, and rinse with DPBS+ 3X. 
5. Add 500 µL of 0.2% Triton-X-100 to permeabalize the cells. Incubate for 10 minutes at 
room temperature. 
6. Aspirate and rinse with DPBS+ 3X.  
7. Aspirate PBS and add 1.5 N HCl (0.5 ml/well for 24-well or 0.25 ml/well for 48-well plate) 
and incubate at RT for 20 min 
8. Wash 3x with PBS, 5 min each 
9. Aspirate DPBS+ and add ice cold (-20C) methanol (1.0 ml/well for 24-well plate).  
Incubate for 10 min at -20°C 
10. Aspirate methanol and wash with 1.0 ml PBS for 10 min (plates can be stored at 4C with 
PBS in wells if analysis is not to be done right away 
11. Dilute anti-BrdU antibody 1:100 in PBS +0.05% Tween-20 
12. Add antibody solution at 150 μl/well for 24-well plate or 75 μl/well for 48-well plate) and 
incubate at RT for 30 min 
13. Aspirate antibody solution and wash 3X with PBS for 5 min each 
14. Add fluorescent dye conjugated secondary antibody diluted 1:500 in PBS+0.05% 
Tween-20 (150 μl/well for 24-well plate or 75 μl/well for 48-well plate) and incubate at RT 
for 30 min 
15. Wash 3X with PBS (without Tween). 
16. Add 0.5 μg/ml Hoechst 33342 to last wash (stock is 1 mg/ml) and incubate for 10 min at 
RT 
17. Aspirate  Hoechst solution, wash w/PBS and add PBS (1 ml/well for 24-well or 0.5 
ml/well for 48-well) 
18. Cells are ready for observation by fluorescence microscopy.  Plates can be stored at 4C 
wrapped in foil to protect from light. 
(“BrdU Cell Proliferation Assay”, 2012) 
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ICC  FOR MYOSIN HEAVY CHAIN ASSAY 
Procedure  
1. Aspirate culture medium and wash cells with DPBS for 1 min. 
2. Add 500 µL of methanol-free formaldehyde into each well. Incubate at room temperature 
for 10 minutes.  
3. Aspirate formaldehyde, and rinse with DPBS+ 3X. 
4. Add 500 µL of 0.2% Triton-X-100 to permeabalize the cells. Incubate for 10 minutes at 
room temperature. 
5. Aspirate and rinse with DPBS+ 3X.  
6. Aspirate PBS and add blocking solution (PBS with 3% FBS or appropriate serum) at 150 
μl per well and incubate at RT for 30 min. 
7. Aspirate blocking solution and rinse with DPBS+ 3X.  
8. Add 1 ml/well ice cold (-20C) methanol and let stand for 10 min. 
9. Aspirate methanol and wash 1.0 ml/well DPBS+ 3X. 
10. Aspirate DPBS+ and add primary antibody (1:500 dilution in PBS/Tween) at 150 μl per 
well and incubate at RT for 30 min.  Secondary antibody-only controls will skip this step 
11. Aspirate primary antibody and wash 4X with PBS for 3 min each wash. 
12. Aspirate PBS and add secondary antibody (diluted 1:500 in PBS/Tween) at 150 μl/well 
and incubate for 30 min 
13. Aspirate secondary antibody solution and wash 4X with PBS.  If nuclear counterstain is 
desired, add Hoechst 33342 at 0.5 μg/ml in PBS to last wash and incubate for 10 min.  
Aspirate Hoechst and add 1 ml/well PBS. 
14. Cells are ready for observation by fluorescence microscopy.  Plates can be stored at 4C 
wrapped in foil to protect from light.  If long term storage is desired replace PBS with 
PBS containing 0.1% Na-Azide to prevent bacterial growth. 
(“Myosin Heavy Chain Immunocytochemistry Protocol”, 2012) 
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ICC FOR MYOD 
Procedure  
1. After cells are fixed in formaldehyde and the antigen is intracellular, permeabilize cells 
by incubating in 0.5 ml of 0.2% Triton X-100 in PBS for 20mins. 
2. Wash each well once 0.5 ml PBS/Tween for 5 mins. 
3. Aspirate PBS and add 0.5ml of blocking solution at room temperature for 15mins ( 
blocking solutions: 3% FBS in PBS). 
4. Wash once with 0.5ml PBS/Tween for 5mins. 
5. Add ice cold Methanol and let stand for 10mins . 
6. Aspirate methanol and was 3 times with PBS/tween. 
7. Incubate with primary antibody (5.2F Mouse monoclonal MyoD Antibody, AbCam) 
diluted 1:1000 in PBS/Tween for 30 mins at RT. 
8. Aspirate primary antibody ad as each well 3 times with 0.5ml of PBS/Tween for 5mins 
each. 
9. Incubate secondary antibody (Alexa Fluor 568 anti-mouse) (at 4ug/ml) for 30 mins in 
PBS/Tween at RT. 
10. Aspirate secondary antibody and was each well four times with 0.5ml PBS for 5 mins 
each 
11. For counterstaining add 0.5ug/ml Hoechst 33342 (for nuclear antigens) to last wash 
(stock is 1mg/ml) and incubate for 10 mins at RT. 
12. Wash two times with 0.5ml PBS for 5 mins each. Add0.1% NaAzide in PBS and store at 
4oC. 
NOTE: Do not counterstain with DAPI if nuclear antigens are to be detected. It is best to 
avoid counterstaining unless specific counts of positive counts of positive cells are to be 
obtained. In this case, counterstain with Hoechst only. 
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SINGLE CELL CONTRACTION ASSAY 
Materials: 
1. Differentiation Media 
2. Calcium Free Non enzymatic cell dissociation buffer ( Sigma C5914) 
3. Carbachol ( Sigma C4382) 
4. Atropine ( Sigma A0132) 
5. Real Time Video 
Methods: 
1. Add 1mL Differentiation Media to the cells and allow 1 week for cells to differentiate.  
2. Add 500uL calcium free non-enzymatic cell dissociation buffer ( Sigma catalog number 
C-5914) and incubate at 37oC for 30 to 40 mins 
3. Add 500uL 1uM Atropine and let sit 5 mins 
4. Add 500uL 10μmol/L Carbachol   
Take Photomicrographs  - the cross sectional surface area of cells when overlapped will show 
which cells contract 
(Pang et al., 1993) 
